ACRIN 6673

Multicenter Feasibility Study of Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients

CRF Set



| ACRIN Study | Case # |
|----------------------|----------------|
| PLACE | E LABEL HERE |
| Institution | Institution No |
| Participant Initials | Case No |

All questions regarding Adverse Events should be directed to ACRIN. All Adverse Events (AEs) and Serious Adverse Events (SAEs) as defined in the protocol require routine reporting via web entry of the AE CRF. In addition, SAEs meeting the criteria for expedited reporting, as specified in the protocol, require (a) telephone report to both NCI and ACRIN within 24 hours of knowledge, (b) AdEERS report completed and submitted as specified in the protocol, and (c) completed AE case report form with investigator's signature submitted to ACRIN via web and filed in the participant chart.

Adeers

| | | | Grade | Attribution | | Submitted for SAEs | Action Taken | Outcome | Date of AE Onset and Resolution |
|-------|---------------------------------------|-----------------------------|--|---|--------------------------------|--------------------|--|--|--|
| | AE Description | AE Short Name CTCAE v3.0 | 1 = Mild 2 = Moderate 3 = Severe 4 = Life threatening or disabling 5 = Fatal | 1 = Unrelated 2 = Unlikely 3 = Possible 4 = Probable 5 = Definite | 1 = Expected 2 = Unexpected | 1 = No 2 = Yes | 1 = None 2 = Medication Therapy 3 = Procedure 4 = Hospitalization 5 = Other | 1 = Recovered 2 = Improved 3 = Ongoing 4 = Death 5 = Unknown | (mm-dd-yyyy); check box "on-going" if the AE is on-going at the time of report |
| Г | | | 0 = 1 dtdi | | | | | | Start date: |
| | | | | | | | | | Resolution date: |
| ľ | | | | | | | | | |
| | | | | | | | | | ☐ On-going |
| | | | | | | | | | Start date: |
| 2 | | | | | | | | | Resolution date: |
| | | | | | | | | | |
| | | | | | | | | | ☐ On-going |
| | | | | | | | | | Start date: |
| 3 | | | | | | | | | Resolution date: |
| ٦ | | | | | | | | | |
| | | | | | | | | | ☐ On-going |
| Cor | nments - for each comment, identify t | the AE number from abov | e (#1-3): | | | | | | |
| | | | | | | | | | |
| | If there are more than 3 AEs for a v | | | | | | | | |
| L | check this box and use another fo | | r Signature | | | | Date | Form Comple | eted (mm-dd-yyyy) |
| "0001 | right 2005" | | | | | | | | AE 01 19 05 1 of |

'copyright 2005' AE 01-18-05 1 of 1

| TL ACRIN 6673 Treatment Labs If this is a revised or corrected form, indicate by checking box. | ACRIN Study 6673 PLACE LABEL HERE Institution Institution No Participant initials Case No |
|---|--|
| Instructions: To be completed at each ablation sess | ion by the Study Interventional Radiologist. Report all "prior" to ablation session. Pages 3 and 4 are completed |
| 1. Date of RFA session: | ate 10 |
| 2. Aspirin and nonsteroidal anti-inflammatory MU medications, antiplatelet medications, or warfarin discontinued prior to the procedure, per Sec 5.3.87 O No, specify reason: O Yes O Participant not taking these medications | |
| 3. Low molecular heparin discontinued 12 hours prio to RFA session, per Sec. 5.3.9 O No, specify reason: O Yes O Participant not taking heparin | r multiple. STOP, SIGN and DATE form. RFA treatment <u>may not</u> commence) |
| 4. Pregnancy test performed, per Sec. 5.3.7.? MULT O No, specify reason: O Yes, results negative Character 40 O Yes, results positive (STOP, SIGN and DATE O Not applicable | STOP, SIGN and DATE form. RFA treatment <u>may not</u> commence) |
| | |
| | |

| TL | ACRIN 6673 Re | vision | | N Study 6673 LABEL HERE | |
|-----------------------|--|----------------------------------|--|--|----------------|
| 5 DD5 | RFASESSIONLABORATORYEVAL | HATIONS. | Institution | Institution No. | |
| | [Performed within 14 days pri | | Participant initials | Case No | |
| 2 do 3 do 98 no | ne, within normal limits ne, abnormal elevated ne, abnormal depressed t done known | Column, reco | rd unit of measure in field provid | t prompted within the Lab Value ded. If unit reports are the same lit of Measure) is to be left blank. | |
| Labs E | valuation Lab Value | Other | Date of test (mm-dd-vyyy) | Normal Range Normal Range | |
| multip | ll. Number of length 4 | Unitof Measure Charader 10 | (date is required for all labs) Doct 10 Mm-dd-Yyyy | LOW HIGH (required for all (required for all abnormal results) abnormal results) Number of length H- | |
| 18 | Platelets # 9 Ku/L | 10 | 11 | 12 13 | |
| INT. | PT 15 seconds | _اله | 17 | 18 19 19 | lost |
| 1 <u>20</u> | PTT 21 L seconds | 32 | _23 | 311 | 5 |
| 1261 | INR 27 L. L % /00 | 28 | <u> 29</u> | 30 31 | _ |
| 1331 | Serum 33 mg/dL 9 | 34 | 35 | _36 / _37/ | |
| 1381 | GGT 39 U/L | 40 | 41 | 42 43 \ num | إبمول |
| 1441 | LDH 45 INL | 46 | 47 | 48 7 49 Jer | ath4 |
| 150 | AFP 51 LL ng/mL | <u>_5</u> 2_ | <u>53</u> · | 54 \ 55 \ floor | at |
| 15e | SGOT 57 U/L | 58 | <u>.59</u> | | mber |
| 169 | SGPT 6 | 64 | <u>65</u> | | H-4 |
| 801 | Total bilirubin | 101 | 71 | 72 7 Aco | 4 5 |
| 1141 | Sodium 75 mmol/L | 16 | <u> </u> | 78 7 79 Num | eryth |
| 180 | Potassium 8 mmol/L | 82 | | 85 7 April | |
| 186 | Chloride <u>\$7</u> mmol/L | 88 | <u>89</u> | 90 91 Num | |
| 1921 | Glucose 93 mg/dL | 94 | 95 | 96) 97) of | : 444 |
| 198 | 8UN 99 mg/dL | 100 | 101 | 102/103/ | • |
| lot 1 | Caldum 105 LL mg/dL | لعاما | <u> </u> | 108 109 | |
| ПОП | Phosphorus | 112 | <u> 113</u> | 114 15 floor | |
| لطلا | Total Protein gm/dt. | 118 | 119 | 190 Tar | , |
| 11997 | Albumin 123 g/dL | <u> 124</u> | 135 | 126 / 127 / | ی م |
| 138 | Ammonia 129 µmol/L | 130 | 131 | 132 13B7 number | M4 |
| 1134 | Hgb 135 L g/dL | 136 | 137 | 138 7 139 7 Apat | 5 |
| 140 | Hct | 143 | 143 | 1447 145 7 PM | my. |
| Ho | Wbc 147 Kul | 148 | 149 | 150 7 151 7 foot | _ |
| "copyr | ight 2005" | | ACRIN | 1 6673 TL 11-01-05 2 of 4 | |

| TL | ACRIN 6673 Treatment Lab | Rev | ision 🗌 | | t Study 6673 LABEL HERE | E |
|---------------|---|----------------|----------------------------|--|---|---|
| | T-RFA SESSION LABO | | | Institution | | |
| 1 do | ormed within two hours ne, within normal limits | after ablation | procedure.] | Participant Initials | Case No | |
| 3 do 98 no | ne, abnormal elevated ne, abnormal depresse t done known | ď | Column, reco | If lab units are other than the rd unit of measure in field prov npted, then Column III (<u>Other U</u> | ided If unit reports | are the same |
| <u>Labs E</u> | valuation Lab Va | ilue | Other Unitof Measure | Date of test (mm-dd-vyyy) (date is required for all labs) | Normal Range LOW (required for all abnormal results) | Normal Range HIGH (required for all abnormal results) |
| 152 | Platelets 153 | 3 Ku/L | 154 | <u>155</u> | 156 | 157 |
| 158 | PT 159 ∐. | seconds | 160 | <u> 161</u> | 1602 | 163 |
| (64) | PTT 165 LL. | seconds | العامال | 167 | 168 | 169 |
| 170 | INR 171 | 」 % | 172 | 173 | 174 | 175 |
| MIN | Serum 177 | mg/dL | 178 | 179 | 180 | 181 |
| 11831 | GGT 18 | 3_Ju/L | 184 | 185 | 186 | 187 |
| 11881 | LDH 18 | 9] [UL | 1901 | 191 | 192 | 193 |
| 494 | AFP 195 LL. | ng/mL | 196 | 147 | 198 | 199 |
| 300 | SGOT Lão | L U/L | 202 | 203 | <u>a et</u> | <u>a05</u> |
| 200 | | | 1808 | ast | 210 | 211 |
| 212 | Total billrubin | Jang/al | 1 <u>4</u> 1 | <u> 215</u> | <u>216</u> | <u>217</u> |
| 218 | Sodium 210 | mmol/L | [220] | <u> </u> | 222 | 223 |
| aa4 | Potassium | A A A | <u>a</u> ab | 221 | 228 | 229 |
| 230 | Chloride \alpha3 | Mmol/L | <u> გპ</u> | <u> 333</u> | 234 | 235 |
| 336 | Glucose [33 | 7 mg/dL | 28 | 239 | 240 | 241 |
| 242 | | - | 244 | <u>a45</u> - | 246 | 247 |
| 1348 | Calcium | ₩g/dL | 250 | 251 | <u>a</u> 52 | <u>253</u> |
| 1354 | Phosphorus | 2-6 | 256 | 251 | <u> 258 </u> | 259 |
| 260 | | | 262 | 263 | 864 | 265 |
| عاملا | Albumin | g/dL | 268 | álf1 | 270 | 271 |
| <u>a7a</u> | Ammonia La73 | µmol/L | 1274 | <u> 275</u> | 276 | 277 |
| 178 | Hgb 279 📖 | g/dL | 280 | 281 | 282 | <u> 283</u> |
| 284 | Hat 285 | % | 284 | 287 | 28B | 289 |
| 1290 | Wbc 29111 | ∐ K/uL | 272 | 293 | 294 | 295 |

| TL ACRIN 6673 Treatment Labs | Revision | PLACE L | Study 6673 ABEL HERE |
|---------------------------------------|---------------------|----------------------|-------------------------|
| | | | Institution No. |
| | | Participant Initials | Case No |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| 291 | o - Character c | 6N | |
| Comments: 041 | b - Crearacter | 2 0 | |
| | | | |
| | | | |
| | | | |
| · · · · · · · · · · · · · · · · · · · | | | |
| | | | |
| | | | |
| | | | 260 Det: 18 |
| 297 - 0 | horacter 25 | Data farms as as | add Dag |
| Signature of Person Responsi | ble for the date | Date form comp | agg Date 18 oleted 3 |
| | | | |
| | | | |
| 302 - | | | |
| Signature of person entering d | active 25 | | |
| "sopurant 2005" | iala unto the web * | | CC72 TI 44 04 0E 4 of A |

| TC ACRIN 6673 Telephone Contact | ACRIN Study 6673 PLACE LABEL HERE |
|--|---|
| If this is a revised or corrected | Participant Initials Case No |
| form, indicate by checking box. | |
| This form is to be completed by the Research Associate at 1 This form is to be completed at 1 Day, 1 Week, 1 Month a | Day, 1 Week, and 1 Month after the initial Ablation Session. nd 3 Months after additional ablation sessions. |
| 2. Reason for contact: Multiple O 1 day post ablation O 21 week post ablation O 31 month post ablation O 43 months post ablation 2a. Date of last RFA session: (mm-dd-yyyy) 3. Participant status: Multiple O 1 Alive (Proceed to Q4) | 3d. Cause of death: Multiple O 1 Progressive/persistent cancer O 2 Complications of protocol treatment O 3 Progressive cirrhosis O 4 Other, specify: (9) Character OquUnknown 4. Performance status (Zubrod Scale) Multiple O 1 Fully active O 2 Ambulatory, capable of light work O 3 In bed less than 50% of the time, capable of self-care, but not of work activities |
| O 2 Transplanted (Complete 3a) O 3 Dead (Complete 3b, 3c, and 3d) O 4 Lost to follow-up; unable to contact (complete 3c) 3a. Date of transplant: (mm-dd-yyyy) (If date of death unknown, code 12-12-2100) 3c. Date of last contact: | On the different of the time, capable of only limited self care Of Bedridden Of Not evaluated Of Unknown 5. Are there any reportable complications/adverse events per Sec 15.7.1 of the protocol? Of No Multiple Office (If yes, an AE form must be completed) RECEIVED Output Office 13 2005 |
| comments: (2) character-60 | AORIN |
| (13) Character 25 Signature of Site Principal Investigator (3) Character 25 Signature of person entering data onto the web? | Date form completed 3 (mm-dd-yyyy) |

ACRIN 6673 RFA-HCC ACRIN Consensus Pathology Read

ACRINSTUDEN 6673 PLACE LABEL HERE

| ACRIN Consensus Pathology Read | Institution | Institution No |
|--|----------------------|----------------|
| If this is a revised or corrected form, indicate by checking box. | Participant Initials | Case No |
| Instructions: This form is completed by the Alternate | ACRIN Pathologist. | |
| 1. Interpretation Date i (mm-dd-yyyy) | | |
| 2. Specimen type (select one) of FNA of Core Needle Biopsy of Resected Hepatic Tissue | | |
| 2a. Specimen ID#: | | |
| 3. Findings | | |
| 3a. Presence of hepatocellular carcinoma (HCC) of Not present (Stop, sign, and date form) of Present of Equivocal | | |
| 3b. Nuclear grade o ! I o \(\lambda \) II o \(\lambda \) III o \(\lambda \) IV | | |
| 3c. Growth pattern (check all that apply) ⟨□ □ Trabecular □ □ Psuedoglandular ⟨□ □ Compact □ □ Fibrolamellar ⟨□ □ Scirrhous ⟨□ □ Mixed | | |
| Comments: | | |
| | | |
| Signature of person entering data onto the web¹ | Date form complete | |
| Printed name of pathologist ² | | (mm-dd-yyyy) |

| | ACRIN 6673 RFA-HCC | |
|----|-----------------------|----------------|
| PL | RFA-HCC | |
| | Local Pathology | Interpretation |

| | | | | | | | | , | ı |
|-----------|-----|---------|------|-----------|-------|--------|---|------|---|
| If this i | s a | revised | or c | corrected | form. | please | V | box. | |

| PLACE LABEL HERE | | | | | |
|----------------------|----------------|--|--|--|--|
| Institution | Institution No | | | | |
| Participant Initials | Case No. | | | | |

ACRIN Study 6673

Instructions: Part A is to be completed by the Research Associate. 'Date form completed' under Part A is the date that questions 1 - 6 under Part A were completed. After completion of Part A, the form and pathologic material are sent to the local pathologist. Part B is to be completed by the local pathologist. 'Date form completed' under Part B is the date that questions 1 - 5a under Part B were

| Part A (completed by site Research Associate) | Part B (completed by the local Pathologist) |
|--|--|
| 1. Procedure Date: | Interpretation Date: |
|) | (P) |
| (mm-dd-yyyy) | (mm-dd-yyyy) |
| 2. Type of Procedure (select one) | 2. Specimen type (select one) |
| of FNA | ot FNA og Core Needle Biopsy |
| and the state of t | od Resected Hepatic Tissue |
| 3 Resected Hepatic Tissue | 3. Specimen ID# (AT) |
| . Couinaud Segment Location | 3. Specimento # |
| (check all that apply for this tumor) | 4. Findings |
| 3 ☐ Segment I | 4a. Presence of hepatocellular carcinoma (HCC) |
| ∳ ☐ Segment II | o t Not present (skip 4b and 4c) |
| | U Tesent |
| | oტ Equivocal |
| Segment MA | 4b. Nuclear grade |
| 7 LI Segment IVB | 011 |
| ▼ □ Segment V | (33) 02 11 |
| २ □ Segment VI | 03 111 |
| N ☐ Segment VII | ou N o ς Unable to determine |
| [[Segment VIII | og chable to determine |
| Specimen ID# (IA) | 4c. Growth pattern (check all that apply) |
| . Opcomon to # | Trabecular |
| 5. Slide ID#(13) | as Psuedoglandular RECEIVE |
| | au Compact SEP 0.7.20 |
| . Tumor#(14) | a7 Fibroiamellar |
| | l ∧v □ Scirrhous |
| | a9 ☐ Mixed ACRIN |
| | 33 ☐ Unable to determine |
| | 392 |
| (S) | 23 |
| omments: | Comments: (30) |
| | |
| | |
| | (Zi |
| (lb) | Date form completed ³ |
| ignature of person responsible for the data ¹ | (mm-dd-yyyy) |
| | (32) |
| ate form completed 3 (17) | Printed name of pathologist |
| (mm-dd-yyyy) | |
| | |
| | |
| ignature of person entering data on to the web 2 | |

| | 30.3511110111211111 |
|-----------------|---|
| P4 | ACRIN 6673 RFA-HCC ACRIN Central Pathology Interpretation |
| If this is a re | evised or corrected form, please $\sqrt{\text{box.}}$ |
| Instructions | : Part A is to be completed by the Research Associate. After |

| ACRIN Study PLACE LABI | 66 EL | 73 HERE | |
|------------------------|----------|------------|--|
| 1 13/1013 11:13- | | | |

| P4 ACRIN 6673 RFA-HCC | PLACE LABEL HERE |
|--|--|
| ACRIN Central Pathology Interpretation | Institution Institution No |
| Actual Contract Contract | Participant Initials Case No |
| If this is a revised or corrected form, please $\sqrt{\text{box.}}$ | |
| Instructions: Part A is to be completed by the Research Associate. After c Part B. Part B will be completed by the Core Pathologist based on the pathologist P4 form and the P1 (pathology report) should be mailed to ACRIN 6664 Data N form is submitted for each tumor. | inic material available. At the tittle of side subitission a copy of the foreign |
| Part A (completed by site Research Associate) | Part B (completed by the ACRIN Pathologist) |
| 1. Procedure Date: | 1. Interpretation Date: (H) (mm-dd-yyyy) |
| 2. Date Specimen sent to Core Lab: (mm-dd-yyyy) 3. Couinaud Segment Location | 2. Specimen type o I FNA o 2 Core Needle Biopsy o 3 Resected Hepatic Tissue |
| (check all that apply for this tumor) 3 Segment I 4 Segment II | 3. Specimen ID # (19) 4. Findings 4a. Presence of hepatocellular carcinoma (HCC) |
| 5 Segment III 6 Segment IVA 7 Segment IVB | o Not present (skip to Q5) o 2 Present o 3 Equivocal |
| Segment ∨ Guarant ∨ Segment ∨ Segment ∨ | 4b. Nuclear grade o!! o2! o2!! o3!!! o4! |
| 4. Specimen ID # (là) | o ≤ Unable to determine RECEIVED 4c. Growth pattern |
| 5. Number of Slides | 22 ☐ Trabecular SEP 0 7 2000 |
| Submitted on this Specimen | Compact Solition Compact Com |
| 6. Tumor # (14) | 5. Agree with local diagnosis of No (complete 5A) o 2 Yes (skip to end) |
| | 5a. Date specimen(s) forwarded to alternate ACRIN pathologist (mm-dd-yyyy) |
| Comments: | Comments: 38 |
| | Date form completed (mm-dd-yyyy) |
| Completed by (Site RA): | Printed name of ACRIN pathologist |

ACRIN 6673 RFA Hepatocelluar Carcinon Initial RFA Treatment Form

| | ACR | IN S | Stl | ıdy | ы | 0/3 | |
|---|-----|------|-----|-----|---|-----|---|
| _ | ~- | _ | | | | | _ |

| RFA Hepatocelluar Carcinoma Initial RFA Treatment Form | PLACE LABEL HERE Institution No |
|--|--|
| If this is a revised or corrected form, indicate by checking box. | Patient's Initials Patient's I.D. No |
| Instructions: This form collects information related to the report dates mm/dd/yyyy. If a response is unknown, reco | • • • • • • • • • • • • • • • • • • • |
| 1 Did the RFA treatment commence? | 3b If RFA did not commence or was |
| 1 No (complete 1a) | not completed, specify reason: |
| 2 Yes | O 1 Patient refused to start treatment |
| Lesion 1 | O 2 Technical problems during procedure |
| Lesion 2 | O 3 RFA treatment initiated but not completed |
| | O 4 RFA treatment not initiated |
| Lesion 3 | O 5 Adverse event or toxicity, specify: |
| 3 Not applicable | |
| 4 K BEA CARLOS AND A STATE OF THE STATE OF T | O 6 Other reason, specify: |
| 1a If RFA treatment did not commence, specify reason wh | ıy: |
| O 1 Patient refused to start treatment | |
| O 2 Technical problemsO 3 Adverse event or toxicity, specify: | 4 **Number of tumors treated: |
| O 3 Adverse event of toxicity, specify. | 0 1 0 2 0 3 |
| O 4 Other reason, specify: | **[Complete an Ablation Treatment Form per tumor treated |
| O 4 Other reason, specify. | _ see pages 3-5.] |
| | |
| 1b Were any adverse events reported | 5 Radiologist ID performing procedure: |
| during this time period: | Tradiologistib performing procedure. |
| O 1 Yes | |
| O 2 No | |
| If <u>ves</u> , specify date: | A |
| (mm-dd-yyyy) | 6 Imaging modality utilized for RFA |
| | O 1 Ultrasound |
| 2 Has the tumor been biopsied? | O 2 CT Scan |
| O No (skip to Q3) | O 3 MRI |
| O Yes | |
| | 7 Was a pregnancy test performed |
| 2a Date of biopsy | (BetahCG blood test) within 24 hours prior to |
| (mm-dd-yyyy) | RFA procedure? |
| | O 1 No (complete 7a) |
| 2b Type of procedure: | O 2 Yes (complete 7b) |
| O 1 FNA | O 3 Not applicable |
| O 2 Core Needle Biopsy | |
| | 7a If no specify: |
| 3 Date of RFA treatment (mm-dd-yyyy) | . , |
| | |
| 3a Was the RFA treatment completed for each tumor? | |
| 1 No (complete 3a) | 7b Test results: |
| 2 Yes | |
| Logion 1 | O 1 Negative |

| 1 | No | (comp | lete 3a) | |
|---|-----|-------|----------|---|
| 2 | Yes | 3 | | |
| | | 1 1 | Lesion | |
| | | | Lesion | 2 |
| | | | Lesion | 3 |
| _ | | | | |

3 Not applicable

O 2 Positive

| l |
|-------|
| ı |
| ı |
| ı |

Study 6673

Case # _____


Revision

8 Complete description of <u>each tumor ablated</u> and indicate location using the diagram, (Appendix VI). Numbering must be consistent throughout the study.

| _ | Assigned Tumor # — — — — | Liver Segment * — — — — | Size (mm) Trans (M-L) x CC (S-1) x AP (A-P) | Subcapsular 1 No 2 Yes | Contiguous to major (< 1 cm) vessels 1 No 2 Yes | |
|---|--------------------------------|-------------------------------|--|------------------------|---|--|
| | | | xx | | | |
| | | | xx | | | |
| | | | xx | | | |

Diagram of the Liver

*Couinaud Segments 1 Segment I 2 Segment III 3 Segment IVA 5 Segment IVB 6 Segment V 7 Segment VI 8 Segment VII 9 Segment VIII



| TF s | study 6673 | Case # | Revision |
|-------------|--------------|--------|--|
| Ablation Tr | eatment Form | | 9d. Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: |
| | | | |

- 9. Tumor ☐ (Record tumor number per diagram)9a. ☐ Number of ablations this session within this tumor
 - 9b. Number of cauterizations for this tumor:

 o 1 o 2 o 3 o 4 o 5 o 6

- o 1 single, 2 cm tip
- o 2 single, 3 cm tip
- o 3 cluster, 3 prong, 2.5 cm tip
- 9e. Were any complications encountered?
 - o No o Yes

If yes, check all that apply:

- o abcess o pneumothorax
- o hemorrahage o tumor seeding
- o other, specify:


| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

Diagram of the Liver

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

9f. Mark location cauterizations on diagram with a "c".




| TF | Study | 6673 | Case # | | Revision | |
|---|---------------------------------|-----------------|--------------------------------|--|--------------------------------|--|
| | Treatmer PLICABLE SKI | | ETE LAST PAGE] | 10d. Indicate Valley Rf Ablation needle o 1 single, 2 cm | les utilized: | |
| 10. Tumor (Record tumor number per diagram) | | | ber per diagram) | o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip | | |
| 10a. _ | Number Not applicable | | this session within this tumor | 10e. Were any comp o No o Yes <u>If yes, check all t</u> | blications encountered? | |
| | | uterizations fo | or this tumor: o 5 o 6 | o abcess o hemorrahage o other, specify: | o pneumothorax o tumor seeding | |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

10f. Mark location cauterizations on diagram with a "c".



| TF | Study 6673 | Case # | Revision | | |
|---|-------------------------|-------------------------------|-------------------------------------|--|--|
| Ablation | n Treatment Form | | 11d. Indicate Valley Lab Cooled Tip | | |
| [IF NOT APPLICABLE SKIP AND COMPLETE LAST PAGE] | | TE LAST PAGE] | Rf Ablation needles utilized: | | |
| | | | o 1 single, 2 cm tip | | |
| 11. Tumo | or 🔲 (Record tumor numb | oer per diagram) | o 2 single, 3 cm tip | | |
| 1 | | | o 3 cluster, 3 prong, 2.5 cm tip | | |
| 112 | Number of ablations the | his specion within this tumor | | | |

11b. Number of cauterizations for this tumor: o 4 o 2 o 3 o 1 o 5

o Not applicable

o No o Yes If yes, check all that apply:

o abcess

o pneumothorax o hemorrahage o tumor seeding

11e. Were any complications encountered?

o other, specify:


| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

Diagram of the Liver

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

11f. Mark location cauterizations on diagram with a "c".



| TF | Study 6673 | Case # | Revision |
|--------------|--|--------------------|------------------------------|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| Comments: | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | Data farm as and a | od 3 |
| Signature of | person responsible for the data ¹ | Date form complete | ed ³ (mm-dd-yyyy) |
| | | | |
| Signature of | person entering data onto the web | O ² | |

RFA-HCC Additional RFA Session Form

ACRIN Study 6673 PLACE LABEL HERE

| | Institution Institution No |
|---|--|
| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | Participant Initials Case No |
| session. A RA Form is completed for each tumor ablated . The ablated tumor and cauterize | Radiologist (the radiologist performing the RFA), for tumors ablated after the initial ablation ation locations are marked within the diagrams (page 2, question 6b) with a "t" and "c"within w.acrin.org a copy of page 2 of the RA form must be mailed to the Data Management Center. |
| 1. Did RFA session commence for this tumor? (Complete one RA from per tumor) O No (Complete Q1a - 2d, then sign and date form) O Yes (Proceed to Q2) 1a. If no give reason: [111] O Participant refused O Technical problems during procedure O RFA deferred O Adverse Event O Claustrophobia O Complications, specify: O Medical reason O Equipment failure O Injection site complications O Unable to visualize lesion O Other reason, specify: [112] 1b. How many tumors were scheduled to be treated? | 2a. Proof of recurrence (select one) [2] O CT (complete Q2b) O Biopsy (complete Q2c and Q2d) 2b. Date of CT scan: (mm-dd-yyyy) [3] 2c. Date of biopsy: (mm-dd-yyyy) [4] 2d. Type of procedure [5] O FNA O Core needle biopsy 3. Date of RFA session: (mm-dd-yyyy) [6] 3a. Reader ID #: [7] 4. Total number of tumors treated this session: [8] (Complete one RA form per tumor) |
| 1c. This form represents tumor number: [115] 1d. Was the participant rescheduled? [116] | 4a. This form represents tumor number: [9] 4b. Imaging modality used for RFA: [10] |
| [116] | O Ultrasound |

- 2. Type of recurrence (select one) [1]
 O Local (faliure of primary ablation)

 - O Remote intrahepatic
 - O Both

O No

O Yes

- 5. Are there any reportable complications / adverse events per Sec. 15.0 of the protocol? [11]
 - O No

O Ultrasound

O CT scan

O MRI

O Yes (AE form must be completed)

| RA | |
|----|--|
|----|--|

RFA-HCC Additional RFA Session Form

If this is a revised or corrected form, please $\sqrt{\text{box}}$.

| ACRI | N Study | 66 | 73 |
|-------|---------|----|----|
| PLACE | | | |


| | Institution | Institution No | | | |
|-------------------------------|--|----------------|--|--|--|
| Doutioinant Initials Coss No. | Post de la contraction de la c | O No | | | |

ABLATION SESSION FORM

Tumor location and numbering must remain consistent throughout study.

- 6. This form represents Tumor Number
 - 6a. Date of Session: _____ ____ (mm-dd-yyyy) [13]
 - 6b. Mark location of this tumor number and cauterization with a "t" and "c" respectively on the diagram below.

Diagram of the Liver (Appendix VI)



- 6c. Was the RFA session completed or attempted for this tumor? $_{[14]}$
 - O No, RFA not completed, no RFA treatment to record (Complete 6d, sign and date form)
 - O Yes, RFA complete (Proceed to Q7)
 - O Yes, RFA attempted and incomplete (Complete 6d and proceed to Q7)
- 6d. If RFA was not completed, specify reason: $_{[15]}$
 - O Participant refused
 - O Technical problems during procedure
 - O RFA deferred
 - O Adverse Event
 - O Claustrophobia

 - O Medical reason
 - O Equipment failure
 - O Injection site complications
 - O Unable to visualize lesion
 - O Other reason, specify: _____

Couinaud Segments:

| Segment | I | Segment | II | Segment | III |
|---------|-----|---------|-----|---------|------|
| Segment | IVA | Segment | IVB | Segment | V |
| Segment | VI | Segment | VII | Segment | VIII |

| DA | RFA-HCC Additional RFA Session Form |
|----|-------------------------------------|
| | Additional RFA Session Form |

If this is a revised or corrected form, please $\sqrt{\text{box}}$.

| ACRIN | l Study | 667 | 73 |
|-------|---------|-----|----|
| PLACE | | | |

| Institution | Institution No. |
|----------------------|-----------------|
| Participant Initials | Case No. |
| | . Case 110. |

Ablation Session Form

7. Complete description of this tumor

| Assigned Tumor Number | Record Session Date | Couinaud Liver Segment (Check all that apply for this tumor) | Size (cm) Largest Size in Diameter | Subcapsular | Contiguous to Major Vessels? (vessels > 5mm) | Number of ablations this session within this tumor | Number of percutaneous punctures during this session |
|-----------------------------|---------------------------|---|---|---------------|--|--|--|
| [17] | [18] | Segment I [19] Segment II [20] Segment III [21] Segment IVA [22] Segment IVB [23] Segment V [24] Segment VI [25] Segment VII [26] Segment VIII [27] | Note: Lesion size recorded on C2 or NT form(s) must remain consistent throughout the study on RA forms. | O No O Yes | O No O Yes | [31] | [32] |

| Λ | RFA-HCC Additional RFA Session Form |
|---|-------------------------------------|
| M | Additional RFA Session Form |

If this is a revised or corrected form, please $\sqrt{\text{box}}$.

ACRIN Study 6673 PLACE LABEL HERE

| Institution | Institution No. |
|----------------------|-----------------|
| Participant Initials | Case No. |
| | . Case 110. |

Note: Required ablations (as per Section 9 of the protocol) less than 12 minutes (16 minutes if using switchbox) will be considered non-compliant according to Section 20.6 of the protocol.

| Ablation Number | Baseline Impedance (R) | Treatment Duration (min) | One minute Post Treatment Temperature (C) | Switch box used? | Switch box cycle number | Indicate Valley Lab Cooled Tip RF ablation needles utilized | Cauterization of needle track performed? If yes indicate location on diagram with a "c" | Number of tumors ablated utilizing switch box | Assigned tumor number of tumors ablated utilizing Switch box (check all that apply) | Are there additional ablations to describe for this tumor? |
|--------------------|---------------------------|-----------------------------|---|-----------------------|-----------------------------------|--|--|---|---|--|
| 1. | [35] | [36] | [37] | [38] O No O Yes | [39] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [33] O No O Yes | [118] O 1 O 4 O 2 O 5 O 3 O 6 | [119] ☐ 1 ☐ 5 ☐ 9 ☐ 2 ☐ 6 ☐ 10 ☐ 3 ☐ 7 ☐ 11 ☐ 4 ☐ 8 ☐ 12 | [40] O No O Yes |
| 2. | [41] | [42] | [43] | O No O Yes | [45] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [121] O No O Yes | [122] O 1 O 4 O 2 O 5 O 3 O 6 | [123] □ 1 □ 5 □ 9 □ 2 □ 6 □ 10 □ 3 □ 7 □ 11 □ 4 □ 8 □ 12 | [46] O No O Yes |
| 3. | [47] | [48] | [49] | O No O Yes | [51] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [126] O 1 O 4 O 2 O 5 O 3 O 6 | [127] 1 | O No O Yes |
| 4. | [53] | [54] | [55] | [56] O No O Yes | [57] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [129] O No O Yes | [130] O 1 O 4 O 2 O 5 O 3 O 6 | [131] 1 | [58] O No O Yes |
| 5. | [59] | [60] | [61] | [62] O No O Yes | [63] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [133] O No O Yes | [134] O 1 O 4 O 2 O 5 O 3 O 6 | [135] 1 | [64] O No O Yes |
| 6. | [65] | [66] | [67] | [68] O No O Yes | [69] O 1 O 4 O 2 O 5 O 3 | [136] O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [138] O 1 O 4 O 2 O 5 O 3 O 6 | [139] 1 | [70] O No O Yes |

| DΛ | RFA-HCC Additional RFA Session Form |
|----|--|
| | Additional RFA Session Form |

| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | |
|--|--|
|--|--|

ACRIN Study 6673 PLACE LABEL HERE

| Institution | Institution No. |
|------------------------|-----------------|
| Participant Initials | Case No. |
| i ai ticipant initiais | . 0030110. |

Note: Required ablations (as per Section 9 of the protocol) less than 12 minutes (16 minutes if using switchbox) will be considered non-compliant according to Section 20.6 of the protocol.

| Ablation Number | Baseline Impedance (R) | Treatment Duration (min) | One minute Post Treatment Temperature (C) | Switch box used? | Switch box cycle number | Cooled Tip RF ablation needle track ablated | | Number of tumors ablated utilizing switch box | Assigned tumor number of tumors ablated utilizing Switch box (check all that apply) | Are there additional ablations to describe for this tumor? |
|--------------------|---------------------------|-----------------------------|---|------------------------|-----------------------------------|--|------------------------|---|---|--|
| 7. | [71] | [72] | [73] | [74] O No O Yes | [75] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [141] O No O Yes | [142] O 1 O 4 O 2 O 5 O 3 O 6 | [143] 1 5 9 2 6 10 3 7 11 4 8 12 | [76] O No O Yes |
| 8. | [77] | [78] | [79] | [80] O No O Yes | [81] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | [144] O No O Yes | [146] O 1 O 4 O 2 O 5 O 3 O 6 | [147] ☐ 1 ☐ 5 ☐ 9 ☐ 2 ☐ 6 ☐ 10 ☐ 3 ☐ 7 ☐ 11 ☐ 4 ☐ 8 ☐ 12 | [82] O No O Yes |
| 9. | [83] | [84] | [85] | [86] O No O Yes | [87] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [150] O 1 O 4 O 2 O 5 O 3 O 6 | [151] 1 | [88] O No O Yes |
| 10. | [89] | [90] | [91] | [92] O No O Yes | [93] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [154] O 1 O 4 O 2 O 5 O 3 O 6 | [155] 1 | [94] O No O Yes |
| 11. | [95] | [96] | [97] | O No O Yes | [99] O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [158] O 1 O 4 O 2 O 5 O 3 O 6 | [159] 1 | [100] O No O Yes |
| 12. | [101] | [102] | [103] | [104] O No O Yes | [105 O 1 O 4 O 2 O 5 O 3 | O Single, 2cm tip O Single, 3cm tip O Cluster 3-prong 2.5 cm tip | O No O Yes | [162] O 1 O 4 O 2 O 5 O 3 O 6 | [163] 1 | |


| RFA-HCC Additional RFA Session Form | ACRINSO PLACE LA | tudy 6673 ABEL HERE | |
|--|----------------------|------------------------|-------|
| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | Institution | | |
| | Participant Initials | Case No | |
| | | | |
| | | | |
| Comments: | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | [106] |
| | | | |
| | | | |
| Signature of Person Responsible for the data | Date form completed | (mm-dd-yyyy) | [108] |
| Signature of Person Responsible for the data | | (IIIII aa yyyy) | |
| | | | |
| [109] | | | |
| Signature of person entering data onto the web | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

ACRIN 6673


ACRIN Study 6673 ACRIN Study 6673

| - | ••• Ci imaging rollow-up rorm | ILAGE | LADLLIILIKL | |
|--------|---|--------------------|--------------------|----------|
| _ | | Institution | Institution No | |
| | his is a revised or corrected m, indicate by checking box. | Patient's Initials | Patient's I.D. No. | <u> </u> |
| | | | | |
| Instru | actions: This form is completed by the Study Radiologist. | | | |
| 1. | RFA Follow-up Time Period O Within 7 days of initial RFA Treatment O 0-3 month O 3-6 month O 6-9 month O 9-12 month O 12-15 month O 15-18 month O Other, specify: 1a. Reason for CT Imaging Follow-up: O Every 3 month visit O Post ablation/re-ablation treatment | | | |
| 2. | O Repeat CT Scan Date of last RFA procedure: | | | |
| | (mm-dd-yyyy) | | | |
| | 2a. Total number of tumors treated since 6 O 1 | enrollment: | | |
| 3. | Date of imaging study: (mm-dd-yyyy) | | | |
| 4. | AFP drawn on same day as CT Scan? O No O Yes (complete 4a) O Not applicable | | | |
| | 4a. AFP lab value ng/ml | | | |
| 5. | Does the CT Scan meet the imaging criteria as outlined in the protocol, section 13.2.1? | | | |
| 0 | No (Answer 5a, stop and sign form) Yes | | | |
| | 5a. <u>If NO</u> , scheduled date of repeat CT: | | | |

(mm-dd-yyyy)



| STUDY 6673 | Case# | Revision |
|------------|-------|----------|
| | | |




| *Couinaud Segments: | | | | | | | |
|---------------------|------|--|--|--|--|--|--|
| Segment | I | | | | | | |
| Segment | II | | | | | | |
| Segment | III | | | | | | |
| Segment | IVA | | | | | | |
| Segment | IVB | | | | | | |
| Segment | V | | | | | | |
| Segment | VI | | | | | | |
| Segment | VII | | | | | | |
| Segment | VIII | | | | | | |
| | | | | | | | |

6. Ablated Tumor Status


[TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number Couinau Liver Segmel (Checkallthatiorthistumo | intra-hepatic tumor status: | tra-hepatic of indicated: does this meet the | | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? | |
|--|------------------------------------|--|-----------------------------------|--|--|---------------|
| Segment Segm | 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | Size of recurrence exceeds 5cm Recurrence adjacent to vital structures Evidence of extrahe- patic tumor Not technichally feasible Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 2 of 20



| STUDY 6673 | Case# | Revision |
|------------|-------|----------|
| | | |



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | I |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |


7. Ablated Tumor Status [TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? |
|-----------------|--|---|-------------------------------|-----------------------------------|--|--|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahepatic tumor □ Not technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 3 of 20



| UDY 6673 | Case# | Revision |
|----------|-------|----------|
| | | |



| *Couinaud Segments: | | | | | | | |
|---------------------|------|--|--|--|--|--|--|
| Segment | 1 | | | | | | |
| Segment | II | | | | | | |
| Segment | III | | | | | | |
| Segment | IVA | | | | | | |
| Segment | IVB | | | | | | |
| Segment | V | | | | | | |
| Segment | VI | | | | | | |
| Segment | VII | | | | | | |
| Segment | VIII | | | | | | |
| | | | | | | | |

8. Ablated Tumor Status


[TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | <u>re-ablation</u> | Are there additional ablated tumors to describe? |
|--|---|-------------------------------------|-----------------------------------|--|--|--|
| □ Segment I □ Segment II □ Segment III □ Segment IVI □ Segment IVI □ Segment VI □ Segment VI □ Segment VII | | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahepatic tumor □ Not technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 4 of 20



| Case# | | Revision |
|-------|--|----------|
|-------|--|----------|



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | I |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |


9. Ablated Tumor Status [TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Number S | Couinaud Liver Segment* heckall that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? |
|----------|---|---|-------------------------------|-----------------------------------|--|--|--|
| | Segment I Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahepatic tumor □ Not technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 5 of 20



| OTLIDA AGEO | | |
|-------------|-------|----------|
| STUDY 6673 | Case# | Revision |



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | 1 |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |


10. Ablated Tumor Status [TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number Couinaud Liver Segment* (Check all that apply forthis tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? |
|---|---|-------------------------------|-----------------------------------|--|---|--|
| Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VIII Segment VIII | | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahe- patic tumor □ No technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 6 of 20



| STUDY 6673 | Caso# | Revision |
|------------|-------|----------|
| 310010013 | Case# | Kevision |



| *Couinaud Segments: | | | | | | |
|---------------------|------|--|--|--|--|--|
| Segment | 1 | | | | | |
| Segment | II | | | | | |
| Segment | III | | | | | |
| Segment | IVA | | | | | |
| Segment | IVB | | | | | |
| Segment | V | | | | | |
| Segment | VI | | | | | |
| Segment | VII | | | | | |
| Segment | VIII | | | | | |
| | | | | | | |

11. Ablated Tumor Status


[TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? |
|-----------------|--|---|-------------------------------------|-----------------------------------|--|---|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahe- patic tumor □ No technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 7 of 20



| Case# | | Revision |
|-------|---|----------|
| | l | |



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | 1 |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |


12. Ablated Tumor Status [TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Checkall that apply for this tumor) | Are there additional ablated tumors to describe? |
|--|---|-------------------------------|-----------------------------------|--|---|--|
| Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment V Segment VI Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahe- patic tumor □ No technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 8 of 20



| Case# Revi | sion |
|------------|------|
|------------|------|



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | I |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |


13. Ablated Tumor Status [TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Check all that apply for this tumor) | Are there additional ablated tumors to describe? |
|-----------------|--|---|-------------------------------------|-----------------------------------|--|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahe- patic tumor □ No technichally feasible □ Not clinically indicated | 1 No 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 9 of 20



| Case# | Revision |
|-------|----------|
| | |



| *Couinaud Segments: | | | | | | |
|---------------------|------|--|--|--|--|--|
| Segment | 1 | | | | | |
| Segment | II | | | | | |
| Segment | III | | | | | |
| Segment | IVA | | | | | |
| Segment | IVB | | | | | |
| Segment | V | | | | | |
| Segment | VI | | | | | |
| Segment | VII | | | | | |
| Segment | VIII | | | | | |
| | | | | | | |

14. Ablated Tumor Status

[TUMOR NUMBERING MUST REMAIN CONSISTENT THROUGHOUT THE STUDY]

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Local intra-hepatic tumor status: | Patterns of recurrence: | Re-ablation indicated: | If YES to Re-ablation does this meet the follow-up criteria as utlined in the rotocol, section 9.5.3 | If No to re-ablation provide reason: (Checkall that apply for this tumor) |
|-----------------|--|---|-------------------------------------|-----------------------------------|--|---|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VII Segment VIII | 1 Tumor Absent 2 Tumor Present 88 Indeterminate | 1 Enlargement 2 Halo 3 Nodule | 1 No 2 Yes 88 Indeterminate | 1 No 2 Yes | □ Size of recurrence exceeds 5cm □ Recurrence adjacent to vital structures □ Evidence of extrahe- patic tumor □ No technichally feasible □ Not clinically indicated |

"copyright 2005" ACRIN 6673 IM 06-22-05 10 of 20


| IM | | | |
|----|------------|-------|----------|
| | STUDY 6673 | Case# | Revision |

15. Is there evidence of Remote Intrahepatic Tumor?

- **O** No (STOP and sign form)
- O Yes (Complete 5a)
- **O** Indeterminate

15a. Number of Remote Intrahepatic Tumor(s)

Diagram of the Liver



| *Couinaud Seo | gments: |
|---------------|---------|
| Segment | 1 |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |

Remote Intrahepatic Tumor

16. Number of New Tumor <u>Complete description of each tumor, and indicate location using diagram.</u>

| Tumor Number | Couinaud Liver Segment* (Check all that apply forthis tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA, provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|---|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |


"copyright 2005" ACRIN 6673 IM 06-22-05 11 of 20



| 0 | | |
|-------|--|--|
| Case# | | |

Revision

Diagram of the Liver



| *Couinaud Segments: | | | | | | | |
|---------------------|------|--|--|--|--|--|--|
| Segment | 1 | | | | | | |
| Segment | II | | | | | | |
| Segment | III | | | | | | |
| Segment | IVA | | | | | | |
| Segment | IVB | | | | | | |
| Segment | V | | | | | | |
| Segment | VI | | | | | | |
| Segment | VII | | | | | | |
| Segment | VIII | | | | | | |
| | | | | | | | |

Remote Intrahepatic Tumor

17. Number of New Tumor


Complete description of each tumor, and indicate location using diagram.

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VIII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 12 of 20



| STUDY 6673 | Case# | Revision |
|------------|-------|----------|
| | | |



| *Couinoud Son | manta. | | | | | | | |
|---------------------|--------|--|--|--|--|--|--|--|
| *Couinaud Segments: | | | | | | | | |
| Segment | I | | | | | | | |
| Segment | II | | | | | | | |
| Segment | III | | | | | | | |
| Segment | IVA | | | | | | | |
| Segment | IVB | | | | | | | |
| Segment | V | | | | | | | |
| Segment | VI | | | | | | | |
| Segment | VII | | | | | | | |
| Segment | VIII | | | | | | | |
| | | | | | | | | |

Remote Intrahepatic Tumor

18. Number of New Tumor <u>Complete description of each tumor, and indicate location using diagram.</u>

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |


"copyright 2005" ACRIN 6673 IM 06-22-05 13 of 20



| Case# | |
|-------|--|
| | |

Revision

Diagram of the Liver



| *Couinaud Segments: | | | | | | | | |
|---------------------|------|--|--|--|--|--|--|--|
| Segment | 1 | | | | | | | |
| Segment | II | | | | | | | |
| Segment | III | | | | | | | |
| Segment | IVA | | | | | | | |
| Segment | IVB | | | | | | | |
| Segment | V | | | | | | | |
| Segment | VI | | | | | | | |
| Segment | VII | | | | | | | |
| Segment | VIII | | | | | | | |
| | | | | | | | | |

Remote Intrahepatic Tumor

18. Number of New Tumor

Complete description of each tumor, and indicate location using diagram.


| Tumor Number | Couinaud Liver Segment* (Checkallthat apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA, provide reason (Check all that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|---|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 14 of 20



Revision

Diagram of the Liver



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | I |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |

Remote Intrahepatic Tumor


19. Number of New Tumor <u>Complete description of each tumor, and indicate location using diagram.</u>

| Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA, provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 15 of 20



| Case# | | Revision |
|-------|--|----------|
|-------|--|----------|



| *Couinaud Segments: | | | | | | |
|---------------------|------|--|--|--|--|--|
| _ | | | | | | |
| Segment | • | | | | | |
| Segment | II | | | | | |
| Segment | III | | | | | |
| Segment | IVA | | | | | |
| Segment | IVB | | | | | |
| Segment | V | | | | | |
| Segment | VI | | | | | |
| Segment | VII | | | | | |
| Segment | VIII | | | | | |
| | | | | | | |

Remote Intrahepatic Tumor

20. Number of New Tumor <u>Complete description of each tumor, and indicate location using diagram.</u>

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |


"copyright 2005" ACRIN 6673 IM 06-22-05 16 of 20



| ^ | | |
|----------------|--|--|
| Case# | | |
| - 0436# | | |

Revision

Diagram of the Liver



| *Couinaud Segments: | | | | | | |
|---------------------|------|--|--|--|--|--|
| Segment | 1 | | | | | |
| Segment | II | | | | | |
| Segment | III | | | | | |
| Segment | IVA | | | | | |
| Segment | IVB | | | | | |
| Segment | V | | | | | |
| Segment | VI | | | | | |
| Segment | VII | | | | | |
| Segment | VIII | | | | | |
| | | | | | | |

Remote Intrahepatic Tumor


21. Number of New Tumor Complete description of each tumor, and indicate location using diagram.

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 17 of 20



| STUDY 6673 | Case# | Revision |
|------------|-------|----------|
| | | |



| *Couinaud Segments: | | | | | |
|---------------------|------|--|--|--|--|
| Segment | I | | | | |
| Segment | II | | | | |
| Segment | III | | | | |
| Segment | IVA | | | | |
| Segment | IVB | | | | |
| Segment | V | | | | |
| Segment | VI | | | | |
| Segment | VII | | | | |
| Segment | VIII | | | | |
| | | | | | |

Remote Intrahepatic Tumor

22. Number of New Tumor


Complete description of each tumor, and indicate location using diagram.

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|--|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment IVA Segment IVB Segment V Segment VI Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |

"copyright 2005" ACRIN 6673 IM 06-22-05 18 of 20



| Case# | | Revision |
|-------|--|----------|
|-------|--|----------|



| *Couinaud Seg | ments: |
|---------------|--------|
| Segment | 1 |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |

Remote Intrahepatic Tumor

23. Number of New Tumor <u>Complete description of each tumor, and indicate location using diagram.</u>

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA. provide reason (Checkall that apply for this tumor) | Are there additional tumors to describe? |
|-----------------|---|-------------------------------------|----------------------|---|---|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | 1 No (Stop and sign form) 2 Yes |


"copyright 2005" ACRIN 6673 IM 06-22-05 19 of 20



| Case# |
|-------|
| |

Revision

Diagram of the Liver



| *Couinaud Segments: | | | | |
|---------------------|------|--|--|--|
| Segment | 1 | | | |
| Segment | II | | | |
| Segment | III | | | |
| Segment | IVA | | | |
| Segment | IVB | | | |
| Segment | V | | | |
| Segment | VI | | | |
| Segment | VII | | | |
| Segment | VIII | | | |

Remote Intrahepatic Tumor

24. Number of New Tumor

Complete description of each tumor, and indicate location using diagram.

| Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Largest size in diameter (cm) | Biopsy Indicated? | Does tumor meet the criteria for RFA treatment as outlined in the Protocol? | If No to RFA, provide reason (Checkall that apply for this tumor) | |
|-----------------|--|-------------------------------------|----------------------|---|---|--------------|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment VI Segment VIII | | 1 No 2 Yes | 1 No 2 Yes 88 Indeterminate | □ Tumor Size exceeds 5 cm. □ Tumor adjacent to vital structures. □ Evidence of extrahepatic tumor □ Not technically feasible □ Not clinically indicated | |
| Comments | 5 | | | | | |
| Signature | of person respo | onsible for the d | lata ¹ | | Date form completed ³ | (mm-dd-yyyy) |

Signature of person entering data onto the web ²

ACRIN 6673 RFA Hepatocellular Cancer Initial Evaluation Form

If this is a revised or corrected form, indicate by checking box.

ACRIN Study 6673 **PLACE LABEL HERE**

| Institution | Institution No |
|--------------------|--------------------|
| Patient's Initials | Patient's I.D. No. |

| Performance status (Zubrod Scale) | 4. Pre-enrollment ima | |
|---|-----------------------------------|-------------------------------|
| O Fully active, able to carry on all predisease activities without restriction. | (performed with O Not done O Done | hin 60 days of RFA treatment) |
| O Restricted in physically strenuous activity | O Done O Unknown | |
| but ambulatory and able to carry out work | | |
| of a light or sedentary nature. | <u>lmaging</u> | Date |
| O Ambulatory and capable of all self-care | imaging | Date |
| but unable to carry out any work activities. | | |
| O Capable of only limited self-care, | Abdominal CT | (mm-dd-yyyy) |
| confined to bed or chair 50% or more of | | (IIIII-dd-yyyy) |
| waking hours. | Hepatic Ultrasound | |
| O Completely disabled O Unknown | (If performed) | (mm-dd-yyyy) |
| O GIRIOWII | | |
| | Chest CT | |
| Diagnosis of Cirrhosis (Check all that apply) | O Negative fo | |
| ☐ Biopsy proof | | r metastatic disease |
| Date of biopsy: (mm-dd-yyyy) | O Positive for | metastatic disease |
| Type of procedure | | |
| ☐ FNA | Other, specify | |
| ☐ Core Needle Biopsy | _ | - |
| | | (mm-dd-yyyy) |
| ☐ Clinical and imaging confirmation | 5. Prior treatment for | · HCC· |
| | O No | ncc. |
| Confirmation of Hepatocelluar carcinoma (HCC) | O Yes (Answe | ar 5a) |
| ☐ Biopsy proof | O Tes (Allswe | 51 Jaj |
| Date of biopsy: (mm-dd-yyyy) | 5a. If yes, sp | pecify treatment: |
| Type of procedure | | |
| ☐ FNA | | |
| ☐ Core Needle Biopsy | 6. Patient a surgical | |
| | | ment Form, Appendix IX) |
| Barcelona imaging criteria: | O No | |
| Radiologic criteria [two coincidental | O Yes | |
| imaging techniques (CT, MRI, US, angio) | | |
| showing > 2 cm arterial enhancing tumor nodul | е | |
| Combined criteria [single imaging technique | | |
| (CT, MRI, US, angio) showing > 2 cm arterial | | |
| enhancing tumor nodule with AFP > 400 ng/m | L | |
| ☐ Tumor growth criteria | | |
| | 1 | |

| ACRIN 6673 | Case # |
|--|----------|
| RFA Hepatocellular Cancer - Initial Evaluation | Revision |
| 7. Baseline Laboratory Evaluations: | |
| [Performed within 14 days prior to RFA] | |
| 1 done, within normal limits | |
| 2 done, abnormal elevated | |
| 3 done, abnormal depressed | |
| 98 not done | |
| | |

| <u>Labs</u> | | <u>Lab Value</u> | Date of test (mm-dd-yyyy) | Normal Range | Normal Range |
|-------------|------------------|------------------|---------------------------------|--|--|
| | | | (date is required for all labs) | LOW (required for all abnormal results) | HIGH (required for all abnormal results) |
| | Platelets | ml | | | |
| | PT | seconds | | | |
| | PTT | seconds | | | |
| | INR | mg/dl | | | |
| | Serum Creatinine | L mg/dl | | | |
| | GGT | u/l | | | |
| | LDH | mg/dl | | | |
| | AFP | ng/ml | | | |
| | SGOT | ∟ u/l | | | |
| | SGPT | u/l | | | |
| | Total bilirubin | mg/dl | | | |
| | Sodium | meg/dl | | | |
| | Potassium | meq/l | | | |
| | Chloride | mea/l | | | |
| | Glucose | mg/dl | | | |
| | BUN | mg/dl | | | |
| | Calcium | mg/dl | | | |
| | Phosphorus | mg/dl | | | |
| | Total Protein | gm/dl | | | |
| | Albumin | gm/dl | | | |
| | Ammonia | g/dl | | | |
| | Hgb | g/dl | | | |
| | Hct | ml/dl | | | |
| | Wbc | L. k/mm³ | | | |
| | | | | | |


| | 11 | |
|---|----|---|
| ı | | ı |

ACRIN 6673

RFA Hepatocellular Cancer - Initial Evaluation

| Case # _ | |
|----------|--|
| Revision | |

Diagram of the Liver (Appendix VI)



| *Couinaud Segments: | | | |
|---------------------|------|--|--|
| Segment | 1 | | |
| Segment | II | | |
| Segment | III | | |
| Segment | IVA | | |
| Segment | IVB | | |
| Segment | V | | |
| Segment | VI | | |
| Segment | VII | | |
| Segment | VIII | | |
| | | | |
| | | | |

8. NUMBER OF TUMORS PRESENT:

Complete description of each tumor and indicate location using the diagrams, (Appendix VI). Numbering must be consistent throughout the study.

| Assigend Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Size (cm) Largest Size in Diameter | Are there additional tumors to describe? |
|-----------------------------|---|--|---|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V Segment V Segment VI Segment VII | | .1 No 2 Yes |


| 1 |
|---|
| |

ACRIN 6673

RFA Hepatocellular Cancer - Initial Evaluation

| Case # _ | |
|----------|--|
| Povision | |

Diagram of the Liver (Appendix VI)



| *Couinaud Seç | gments: |
|---------------|---------|
| Segment | 1 |
| Segment | II |
| Segment | III |
| Segment | IVA |
| Segment | IVB |
| Segment | V |
| Segment | VI |
| Segment | VII |
| Segment | VIII |
| | |

Complete description of each tumor and indicate location using the diagrams, (Appendix VI).
 Numbering must be consistent throughout the study.


| Assigend Tumor Number | Couinaud Liver Segment* (Checkall that apply for this tumor) | Size (cm) Largest Size in Diameter | Are there additional tumors to describe? |
|-----------------------------|--|--|---|
| | □ Segment I □ Segment II □ Segment IVA □ Segment IVB □ Segment V □ Segment V □ Segment VI □ Segment VIII | | .1 No 2 Yes |

| 1 |
|---|
| • |

ACRIN 6673 RFA Hepatocellular Cancer - Initial Evaluation

| Case # | |
|----------|--|
| Revision | |

Diagram of the Liver (Appendix VI)



| *Couinaud Segments: | | | |
|---------------------|------|--|--|
| Segment | I | | |
| Segment | II | | |
| Segment | III | | |
| Segment | IVA | | |
| Segment | IVB | | |
| Segment | V | | |
| Segment | VI | | |
| Segment | VII | | |
| Segment | VIII | | |
| | | | |

10. Complete description of each tumor and indicate location using the diagrams, (Appendix VI).

Numbering must be consistent throughout the study.

| Assigend Tumor Number | Couinaud Liver Segment* (Check all that apply for this tumor) | Size (cm) Largest Size in Diameter |
|-----------------------------|--|--|
| | Segment I Segment II Segment III Segment IVA Segment IVB Segment V | |

| Comments: | |
|---|---|
| Signature of person responsible for the data ¹ | Date form completed ³ 20 (mm-dd-yyy |

Signature of person entering data onto the web ²



ACRIN Study 6673 PLACE LABEL HERE

| Additional RFA Treatment Form | Institution | Institution No |
|---|---------------------------|-----------------------------|
| If this is a revised or corrected form, indicate by checking box. | Patient's Initials | Patient's I.D. No |
| Instructions: This form collects information related and report dates mm/dd/yyyy. | I to the RFA Treatment. U | se code table when provided |
| Tumor recurrence o No (skip to Q2) o Yes | | |
| 1a. Proof of recurrence o CT o Biopsy | | |
| Type of recurrence o Local (failure of primary abalation) o Remote o Both | | |
| 2. Date of RFA treatment: 20 (mm-dd-20yy) | | |
| 3. Did the Re-ablation treatment commence? o No* (complete 3b) o Yes | | |
| 3a. Was the Re-ablation treatment completed?o No* (complete 3b)o Yes | | |
| 3b. *If RFA did not commence or was not completed, specify reason: o Patient refused to start treatment o Technical problems during procedure o Adverse event o Other reason, specify: | | |
| 3c. Were any adverse events reported during this time period: O 1 Yes | | |
| O 2 No If <u>yes</u> , specify date: | | |
| (mm-dd-yyyy) | | |
| 4. Radiologist ID performing procedure: | | |
| | | |
| Imaging modality utilized for RFA o Ultrasound | | |

o CT Scan o MRI

| FO | Study 6673 | Case # | Revision |
|----|------------|--------|----------|
|----|------------|--------|----------|


7 Complete description of <u>each tumor ablated</u> and indicate location using the diagram (appendix VI). Numbering must be consistent throughout the study.

| Assigned Tumor # | Liver Segment * | Type of recurrence 1 Local 2 Remote | Size (mm) Trans (M-L) x CC (S-I) x AP (A-P) | Subcapsular 1 No 2 Yes | Contiguous to major (< 1 cm) vessels 1 No 2 Yes | Number of previous RFA sessions |
|---------------------|--------------------|-------------------------------------|---|------------------------------|--|---------------------------------|
| | | | x x | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | xx | | | |
| | | | | | | |

Diagram of the Liver Appendix VI

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




| - O | Study 6673 | Case # | | _ | Revision |
|----------------|--------------------------|-----------------------------|---------|----------------------------|---------------------------------------|
| | reatment Form | | 04 | Indicate Valley L | ah Coolod Tin |
| | | | ou. | Rf Ablation need | • |
| . Tumor 🔲 | (Record tumor numb | per per diagram) | | o 1 single, 2 cm | |
| | • | | | o 2 single, 3 cm | tip |
| 8aN | lumber of ablations t | his session within this tum | or | o 3 cluster, 3 pro | ng, 2.5 cm tip |
| | | | 8e. | Were any compl | ications encountered? |
| o. | lood on a food on DEA | | | o No o Yes | |
| 8b N | number of prior RFA s | sessions for this tumor | | <u>lf yes, check all t</u> | hat apply: |
| | | | | o abcess | o pneumothorax |
| 8c. Numbe | er of cauterizations for | this tumor: | | o hemorrahage | o tumor seeding |
| o 1 | 02 03 04 | 05 06 | | o other, specify: | |
| | | | | | · · · · · · · · · · · · · · · · · · · |
| Ablatio | on Baseline | Treatment Duration | One Min | ute Post Treatment | Number of |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




| FO | Study | 6673 | Case # | | Revision |
|------------------------|-------------|---|-------------------------------|-----|---|
| Ablation [IFNOT APP | | | ETE LAST PAGE] | 9d. | Indicate Valley Lab Cooled Tip Rf Ablation needles utilized: o 1 single, 2 cm tip |
| 9. Tumor | (Record | d tumor numb | er per diagram) | | o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip |
| 9a. 🔟 | | | nis session within this tumor | 9e. | Were any complications encountered? o No o Yes |
| | nber of cau | of prior RFA s iterizations for 0 3 0 4 | | | o abcess o pneumothorax o hemorrahage o tumor seeding o other, specify: |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII




| FO | Study | 6673 | Case # | Revision | | |
|-----------------|--------------|------------------|------------------------------------|--|--|--|
| <u>Ablation</u> | n Treatme | ent Form | | 10d. Indicate Valley Lab Cooled Tip | | |
| [IF NOT AP | PLICABLES | KIP AND CO | MPLETE LAST PAGE] | Rf Ablation needles utilized: | | |
| ĮII IVOTAI | T EIO/(DEE O | 1011 71142 00 | WI LETE ENOTT NOE | o 1 single, 2 cm tip | | |
| 10 Tumo | (Boos | and turns on the | number per diagram) | o 2 single, 3 cm tip | | |
| io. Tumo | r (Recc | ora tumor i | iumber per diagram) | o 3 cluster, 3 prong, 2.5 cm tip | | |
| 10a. | Numbe | er of ablation | ons this session within this tumor | 10e. Were any complications encountered? | | |
| | | | | o No o Yes | | |
| 10b. | Numbe | er of prior R | RFA sessions for this tumor | If yes, check all that apply: | | |
| 40- N | | | and the day of the terms of | o abcess o pneumothorax | | |
| | | | ns for this tumor: | o hemorrahage o tumor seeding | | |
| 0 | 1 o 2 | 03 0 | 4 05 06 | o other, specify: | | |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



| FO | Study 6673 | Case # | Revision | | |
|---|---------------------|--------------------------------|---|--|--|
| Ablati | on Treatment Form | | 11d. Indicate Valley Lab Cooled Tip | | |
| [IF NOT APPLICABLE SKIP AND COMPLETE LAST PAGE] | | LETELAST PAGE1 | Rf Ablation needles utilized: | | |
| | | <u>LETE ENOTT NOE</u> j | o 1 single, 2 cm tip | | |
| 44 T | | | o 2 single, 3 cm tip | | |
| 11. Tumor ☐ (Record tumor number per diagram) | | nber per diagram) | o 3 cluster, 3 prong, 2.5 cm tip | | |
| 11a. | Number of ablations | this session within this tumor | 11e. Were any complications encountered? o No o Yes | | |

11b. Number of prior RFA sessions for this tumor11c. Number of cauterizations for this tumor:

01 02 03 04 05 06

If yes, check all that apply:

o abcess o pneumothorax o hemorrahage o tumor seeding


o other, specify:

| | | | | <u> </u> |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

Diagram of the Liver

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



| FO | Study | 6673 | Case # | Revision | |
|------------|-------------|------------------|--------------------------------|--|--|
| Ablatio | n Treatme | ent Form | | 12d. Indicate Valley Lab Cooled Tip | |
| [IF NOT AF | PPLICABLE S | KIP AND COMPL | ETE LAST PAGEI | Rf Ablation needles utilized: | |
| | | | , | o 1 single, 2 cm tip | |
| | | | | o 2 single, 3 cm tip | |
| 12. Tumo | or (Reco | ord tumor num | ber per diagram) | o 3 cluster, 3 prong, 2.5 cm tip | |
| 12a. | Numbe | er of ablations | this session within this tumor | 12e. Were any complications encountered? | |
| | | | | o No o Yes | |
| 12b. | Numbe | er of prior RFA | sessions for this tumor | If yes, check all that apply: | |
| | | | | o abcess o pneumothorax | |
| 12c. N | lumber of c | auterizations fo | r this tumor: | o hemorrahage o tumor seeding | |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

1 Segment I

o 1

0 2

o 3 o 4


0 5

06

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

12f. Mark location cauterizations on diagram with a "c".

o other, specify:




| FO Study 6673 | Case # | | Revision |
|--|------------------------|---|------------------------------|
| Ablation Treatment Form [IF NOT APPLICABLE SKIP AND COMPLETE LAST | [PAGE] | 13d. Indicate Valley I Rf Ablation needl o 1 single, 2 cm f | es utilized: |
| 13. Tumor (Record tumor number per | diagram) | o 2 single, 3 cm to 3 cluster, 3 prod | • |
| 13a. Number of ablations this sess | sion within this tumor | 13e. Were any comp | lications encountered? |
| 13b. Number of prior RFA session | s for this tumor | If yes, check all the | nat apply: o pneumothorax |
| 13c. Number of cauterizations for this tur | | o hemorrahage o other, specify: | o tumor seeding |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



| FO | Study | 6673 | Case # | Revis | ion 🗌 |
|---|--------------|----------------------------------|----------------------|--------------------------------|---------|
| Ablatio | n Treatme | ent Form | | 14d. Indicate Valley Lab Coole | d Tip |
| [IF NOT APPLICABLE SKIP AND COMPLETE LAST PAGE] | | Rf Ablation needles utilized | i: | | |
| | | ILLASTI AGL | o 1 single, 2 cm tip | | |
| 14. Tumor (Record tumor number per diagram) | | o 2 single, 3 cm tip | | | |
| | | o 3 cluster, 3 prong, 2.5 cm tip | | | |
| 14a. Number of ablations this session within this tumor | | 14e. Were any complications | encountered? | | |
| | | is session within this turnor | o No o Yes | | |
| 14b. Number of prior RFA sessions for this tumor | | If yes, check all that apply: | | | |
| | | | o abcess o pneun | nothorax | |
| 14c. N | lumber of ca | auterizations for | this tumor: | o hemorrahage o tumor | seeding |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

1 Segment I

o 1

02 03


05

o 6

- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII

14f. Mark location cauterizations on diagram with a "c".

o other, specify:




| FO | Study | 6673 | Case # | Revision |
|-----------------|------------|----------------|--------------------------|--|
| Ablation | Treatme | nt Form | | 15d. Indicate Valley Lab Cooled Tip |
| [IF NOT APP | LICABLE SK | IP AND COMP | LETE LAST PAGE] | Rf Ablation needles utilized: o 1 single, 2 cm tip |
| 15. Tumor | ∐ (Recor | rd tumor nui | nber per diagram) | o 2 single, 3 cm tip o 3 cluster, 3 prong, 2.5 cm tip |
| 15a. 🔲 | Number | of ablations | this session within this | tumor 15e. Were any complications encountered? |
| 15b. | Number | of prior RFA | sessions for this tumor | If yes, check all that apply: o abcess o pneumothorax |
| 15c. Nu | mber of ca | uterizations f | or this tumor: | o hemorrahage o tumor seeding |
| o 1 | o 2 | 03 04 | 05 06 | o other, specify: |

| Ablation Number | Baseline Impedance (R) | Treatment Duration (minutes) | One Minute Post Treatment Temperature(°C) | Number of Needle Insertions |
|--------------------|---------------------------|------------------------------|--|--------------------------------|
| 1 | | | | |
| 2 | | | | |
| 3 | | | | |
| 4 | | | | |
| 5 | | | | |
| 6 | | | | |
| 7 | | | | |
| 8 | | | | |
| 9 | | | | |
| 10 | | | | |

*Couinaud Segments

- 1 Segment I
- 2 Segment II
- 3 Segment III
- 4 Segment IVA
- 5 Segment IVB
- 6 Segment V
- 7 Segment VI
- 8 Segment VII
- 9 Segment VIII



| FO | Study 6673 | Case # | | Revision |
|--------------|--|--------|----------------------------------|------------------|
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Comments: | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| | | | | |
| Signature of | person responsible for the data ¹ | | Date form completed ³ | (mm-dd-yyyy) |
| Š | | | | |
| Signature of | person entering data onto the web | 2 | | |
| | | | | |

"copyright 2005"



ACRIN Study 6673 PLACE LABEL HERE

| Institution | Institution No. |
|----------------------|-----------------|
| Participant Initials | Case No. |

If this is a revised or corrected form, please $\sqrt{\text{box.}}$

| nstructions: The F2 form is completed at 6, 9, 12, 15 and 18 moubmitted via the ACRIN website. | nths post initial RFA procedure by the Research Associate, and |
|---|--|
| Did the participant return for the scheduled follow-up? O No (Answer 1a, and 1b) O Yes (Answer 1c) 1a. If no, specify reason: O Participant refusal O Participant unable to be contacted O Unable to be performed and rescheduled O Other, specify: 1b. Date of last centact: | 4. Participant status: [13] O Alive (Complete 4a) O Dead (Complete 4a, 4c, and 4d) O Unknown/unable to contact (Complete 4a) 4a. Was the liver: [14] O Transplanted (Complete 4b) O Resected (Complete 4b) O Neither O Unknown |
| 1b. Date of last contact: ——————————————————————————————————— | 4b. Date of transplant / resection: |
| O 6 months O 9 months O 12 months O 15 months O 18 months O Other, specify: | 4d. Cause of death: [19] O Progressive/persistent cancer O Complications of protocol treatment O Progressive cirrhosis O Other, specify: |
| 3b. Date of most recent Post-ablation CT scan: ——-——- (mm-dd-yyyy) [11] 3c. Are there any reportable complications / adverse events per Sec. 15.7.1 of the protocol? O No O Yes (If yes, an AE form must be completed) | capable of self-care, but not of work activities O In bed greater than 50% of the time, capable of only limited self care O Bedridden O Not evaluated O Unknown |

| ACRIN 6673 RFA-HCC Follow-up Form |
|-----------------------------------|
| If this is a revised or correcte |
| |

| F | RFA-HCC Follow-up Form | PLACE LABEL HERE | | |
|------|--|--|--|--|
| 14 | , , | Institution | Institution No | |
| If 1 | his is a revised or corrected form, please √box. | Participant Initials | Case No | |
| 6. | Any non-protocol treatment started during this follow-up time period: O No (proceed to Q7) O Yes (If yes, complete Q6a) O Unknown (proceed to Q7) 6a. Treatment Date started | | · | |
| | (check all that apply) (mm-dd-yyyy) | ☐ Evidence o | of extrahepatic tumor [43] | |
| | ☐ Chemotherapy [23] —— [24] | | cally feasable / not dicated | |
| | ☐ Start date of Chemotherapy unknown [25] | clinically indicated [44] No local or remote intrahepatic tumor visible [4] | | |
| | Radiation to Non-Study _[26] [27] | | ne week of CT Scan? [46] | |
| | Start date of Radiation to Non-Study Site unknown [28] | O No, specify reas | on _[47] | |
| | Specify Non-Liver site:[29] | O Yes (answer Q8a | a and Q8b) | |
| | Other treatment, [30] [31] | 11a. Date drawn: | (mm-dd-yyyy) _{[44} | |
| | ☐ Other treatment start date unknown [32] Specify treatment: [33] | 11b. AFP lab valu | e: ng/ml _[49] | |
| 7. | Were there any tumor biopsies performed during this time period? [34] O No (proceed to Q8) O Yes (Answer Q7a and Q7b, submit per Sec 11.3 of the protocol) O Yes, previously submitted (Answer Q7a and Q7b) O Unknown 7a. Date of biopsy: (mm-dd-yyyy) [35] Date of biopsy unknown [36] 7b. Type of procedure [37] O FNA O Core needle | since the pre O No O Yes, lab | lab value increased or decreased evious follow-up visit? [50] value increased value decreased | |
| 8. | Is there evidence of local intrahepatic tumor on the corresponding CT exam for this visit? [38] O No O Yes O Indeterminate | Name of person responsib | ole for the data [52] | |
| 9. | Is there evidence of remote intrahepatic tumor on the corresponding CT exam for this visit? [39] O No O Yes | Date Form Completed (mr | [53] n-dd-yyyy) | |
| 10. | Will/has this participant been scheduled for reablation? O No O Yes | Name of person entering of | data on web | |



ACRIN Study 6673

| RFA-HCC | PLACE LABEL HERE | | |
|--|--|--|--|
| Follow-up Form | Institution Institution No | | |
| If this is a revised or corrected form, indicate by checking box. | Patient's Initials Patient's I.D. No | | |
| Instructions: The F1 form is completed at day 1 post initial RFA procedure by the Research Ass | , 1 week, 1 month, 3, 6, 9, 12, 15 and 18 months ociate. | | |
| 1. RFA Follow-up Time Period: | 4. Cause of death: | | |
| O 1 1 day | O 0 Alive | | |
| O 2 1 week | O 1 Progressive/persistent cancer | | |
| O 3 1 month | O 2 Complications of protocol treatment | | |
| O 4 0-3 months | O 3 Both cancer and protocol treatment | | |
| O 5 3-6 months | O 4 Progressive cirrhosis | | |
| O 6 6-9 months | O 5 Other, specify | | |
| O 7 4-12 months | O 99 Unknown | | |
| O 8 12-15 months | O 99 OHKHOWH | | |
| O 9 15-18 months | 5. Tumor number: | | |
| O 10 Other, specify: | | | |
| | 0 1 0 3 0 5 0 7 | | |
| 1a. Reason for follow-up: | 0 2 0 4 0 6 0 8 | | |
| O 1 Telephone contact | | | |
| O 2 Every 3 month visits | 6. Performance status (Zubrod Scale) | | |
| O 3 RFA treatment | O 0 Fully active | | |
| O 4 Post-ablation CT scan | O 1 Ambulatory, capable of light work | | |
| o i rost ablation o rosan | O 2 In bed less than 50% of the time, capable | | |
| 1b. RFA treatment date: | of self-care, but not of work activities | | |
| | O 3 In bed greater than 50% of the time, | | |
| - (mm-dd-yyyy) | capable of only limited self care | | |
| | O 4 Bedridden | | |
| 1c. Date of Post-ablation CT scan: | O 98 Not evaluated | | |
| | O 99 Unknown | | |
| (mm-dd-yyyy) | | | |
| 1d. Were any adverse events reported | 7. Did the participant return for the scheduled follow-up? | | |
| during this time period: | O 1 No (specify reason, STOP and sign form) | | |
| O 1 Yes | O Participant refusal | | |
| O 2 No | O Participant unable to be contacted | | |
| If <u>yes</u> , specify date: | O Unable to be performed and rescheduled | | |
| | O 2 Yes | | |
| (mm-dd-yyyy) | O Completed | | |
| 2. Date of evaluation: | O Incomplete, will return on: | | |
| (mm-dd-yyyy) | · | | |
| 3. Patient status: | | | |
| O 1 Alive | (mm-dd-yyyy) | | |
| O 2 Transplanted | O Incomplete, return date unknown | | |
| O 3 Dead | if <u>No</u> - specify reason: | | |
| O 4 Lost to follow-up (unable to contact) | | | |
| O + LOSt to follow up (unable to contact) | | | |
| 3a Status Dato: | | | |
| 3a. Status Date: | | | |

(mm-dd-yyyy)

(Date of death if dead, date of transplant if transplanted, or last date known alive if alive or lost.)

| F1 |
|----|
|----|

Study 6673

Case # _____

Revision

| <u>9.</u> | Pre-RFA | Treatment Laboratory | / Evaluations: |
|-----------|---------|----------------------|----------------|
| | | | |

[Performed within 14 days prior to RFA]

- 1 done, within normal limits
- 2 done, abnormal elevated
- 3 done, abnormal depressed
- 98 not done
- 99 unknown

| <u>Labs Evaluation</u> <u>La</u> | | <u>Lab Value</u> | <u>Date of test (mm-dd-yyyy)</u> (date is required for all labs) | Normal Range LOW (required for all abnormal results) | Normal Range HIGH (required for all abnormal results) |
|----------------------------------|------------------|------------------|---|---|--|
| | Platelets | ml | | | |
| | PT | seconds | | | |
| | PTT | seconds | | | |
| | INR | mg/dl | | | |
| | Serum Creatinine | mg/dl | | | |
| | GGT | u/l | | | |
| | LDH | mg/dl | | | |
| | AFP | ng/ml | | | |
| | SGOT | ∟ u/l | | | |
| | SGPT | ∟ u/l | | | |
| | Total bilirubin | mg/dl | | | |
| | Sodium | meg/dl | | | |
| | Potassium | meq/l | | | |
| | Chloride | mea/l | | | |
| | Glucose | mg/dl | | | |
| | BUN | mg/dl | | | |
| | Calcium | mg/dl | | | |
| | Phosphorus | mg/dl | | | |
| | Total Protein | gm/dl | | | |
| | Albumin | gm/dl | | | |
| | Ammonia | g/dl | | | |
| | Hgb | . g/dl | | | |
| | Hct | ml/dl | | | |
| | Wbc | . k/mm³ | | | |
| | Beta hCg | . k/mm³ | | | |

| F1 |
|----|
|----|

Study 6673

Case # _____

Revision

| 9. | Post RFA | Treatment | Laboratory | Evaluations : |
|----|-----------------|------------------|------------|----------------------|
|----|-----------------|------------------|------------|----------------------|

[Performed within 14 days prior to RFA]

- 1 done, within normal limits
- 2 done, abnormal elevated
- 3 done, abnormal depressed
- 98 not done
- 99 unknown

| <u>Labs E</u> | <u>valuation</u> | <u>Lab Value</u> | Date of test (mm-dd-yyyy) (date is required for all labs) | Normal Range LOW (required for all abnormal results) | Normal Range HIGH (required for all abnormal results) |
|---------------|------------------|------------------|---|---|---|
| | Platelets | mI | | | |
| | PT | seconds | | | |
| | PTT | seconds | | | |
| | INR | . mg/dl | | | |
| | Serum Creatinine | mg/dl | | | |
| | GGT | L u/I | | | |
| | LDH | mg/dl | | | |
| | AFP | ng/ml | | | |
| | SGOT | u/l | | | |
| | SGPT | u/l | | | |
| | Total bilirubin | . mg/dl | | | |
| | Sodium | meg/dl | | | |
| | Potassium | . meq/l | | | |
| | Chloride | mea/l | | | |
| | Glucose | mg/dl | | | |
| | BUN | mg/dl | | | |
| | Calcium | . mg/dl | | | |
| | Phosphorus | mg/dl | | | |
| | Total Protein | gm/dl | | | |
| | Albumin | gm/dl | | | |
| | Ammonia | g/dl | | | |
| | Hgb | g/dl | | | |
| | Hct | ml/dl | | | |
| | Wbc | . k/mm³ | | | |
| | | | | | |

| \equiv | |
|----------|-----|
| | - 4 |
| | -1 |
| | _ |
| - | _ |
| | |
| | |

Revision

| 10. | Any non-protocol treatment started during thi | S |
|-----|---|---|
| | follow-up periods: | |

- O 1 No
- O 2 Yes (if yes, complete 11a)
- O Unknown

| 10a. | <u>Treatment</u> | Date started (mm-dd-yyyy) |
|------|---------------------------------------|---------------------------|
| | Hormones | |
| | ☐ Chemotherapy | |
| | Radiation to Non-Study Site, Specify: | |
| | Other treatment, Specify: | |

| Comments: | | | |
|-----------|--|--|--|
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Signature of person responsible for the data ¹ (mm-dd-yyyy)

Signature of person entering data onto the web ²



PLACE LABEL HERE

| —— interpretation Form | | |
|---|----------------------|----------------|
| | Institution | Institution No |
| If this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No |
| · | | |

Instructions: The central reader is to review the abdominal scans for each case and complete one CX form at each imaging timepoint to document tumors and tumor descriptors. All dates are reported as MM/DD/YYYY. All responses are required unless otherwise

| oted. This form will be completed and data entered at ACRIN hear The ACRIN Case Number and Follow-Up Time Period must be red | |
|---|---|
| The ACININ Case Number and Follow-op Time Ferrou must be rec | corded on all pages of this form. |
| Section I. | Section II. |
| . RFA Follow-up Time Period [1] ○ 1 Pre-enrollment ○ 2 Baseline (initial post-ablation) ○ 3 3 Month ○ 4 6 Month ○ 5 9 Month ○ 6 12 Month ○ 7 15 Month ○ 8 18 Month ○ 88 Other, specify | 4. Is there evidence of new Extrahepatic Tumor(s)? ○ 1 No (skip Q4a) ○ 2 Yes (complete Q4a and Section III) 4a. Specify location(s): [mark all that apply: □ = 1 Not Marked, □ = 2 Marked] □ Adrenal gland [16] □ Kidney [17] □ Lung [18] □ Lymph node [19] □ Musculoskeletal [20] □ Pancreas [21] □ Peritoneum [22] □ Spleen [23] □ Abdominal wall [24] □ Other, [25] specify [26] |

| | ACRIN 6673 |
|----|---------------------|
| CX | Central Reader |
| | Interpretation Form |
| | |

PLACE LABEL HERE

| , — | Institution | Institution No. |
|--|----------------------|-----------------|
| f this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No |
| · · · · · · · · · · · · · · · · · · · | | |

Section III.

TUMOR REPORT

- * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|--|--|--|---------------------------------------|
| [27] | [28] | O 1 Ablated O 2 Not ablated | | [39] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [40] O 1 No O 2 Yes | [41] |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVB | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | · | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | · | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VI Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |

"Copyright 2009" Version 3.0 6673 CX 09-08-09 2 of 6



PLACE LABEL HERE

| , — | Institution | Institution No. ———— |
|--|----------------------|----------------------|
| this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No. |
| | | |

TUMOR REPORT

- * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|--|--|---|---------------------------------------|
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VI Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |

"Copyright 2009" Version 3.0 6673 CX 09-08-09 3 of 6

| | ACRIN 6673 |
|----|---------------------|
| CX | Central Reader |
| | Interpretation Form |
| | |

PLACE LABEL HERE

| , | Institution | Institution No. ———— |
|--|----------------------|----------------------|
| this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No |
| | | |

TUMOR REPORT

- * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|--|--|--|---------------------------------------|
| | · | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | · | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVB | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |
| | | O 1 Ablated O 2 Not ablated | Segment I Segment V Segment II Segment VI Segment III Segment VII Segment IVA Segment VIII Segment IVA | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | O 1 No O 2 Yes | |

"Copyright 2009" Version 3.0 6673 CX 09-08-09 4 of 6

| ACRIN 6673 |
|---|
| Central Reader |
| ACRIN 6673 Central Reader Interpretation Form |
| |

If this is a revised or corrected form, please $\sqrt{\text{box}}$.


| ACR | 6673 | | |
|--------------|------|------|----|
| PLACE | LABE | L HE | RF |

Institution _____ Institution No.____

Participant Initials _____ Case No. ____

Instructions:


- 1) Mark tumor location(s) on the diagram by encircling the tumor number. Example for Tumor #1
- 2) Mark cauterization location(s) on the diagram with a "c" encircled. Example (C)
- 3) Tumor numbering and locations must be consistent throughout central reader interpretation across all follow-up time periods.





PLACE LABEL HERE

| If this is a revised or corrected form, please $\sqrt{\text{box.}}$ | | Institution No |
|---|-------------|--|
| Section IV. | | |
| Comments: | | |
| [43] | | [42] ———————————————————————————————————— |
| Reader Initials | | Date form completed (mm-dd-yyyy) |
| Initials of person completing form | | |
| Section V: (ACRIN personnel only) | | |
| This section is completed <u>after tumor matching</u> , by the ACRIN RA. | | |
| Adjudicator review required if Central reader and Local reader disa | gree about: | |
| 1. the presence of disease. | | |
| the size of tumors (tumor size must be within 50% of the central was >3cm or <1cm then it would require adjudic | | ocal measure was 2 cm and the |
| 3. the number of tumors. | | |
| the couinaud segment location of tumors (tumors must I segment II and the Central was in segment V then it wo | | segment, i.e: if the local was in |
| 5. the Central reader found a tumor missed by the Local re | eader. | |
| 6. the Local reader found a tumor missed by the Central re | eader. | |
| Is adjudicator review required? [46] | | |
| o No o Yes | | |
| Initials of person responsible for the data | | Date form completed (mm-dd-yyyy) |



| Chest C1 Imaging Form | | PLACE LABEL HERE | | |
|-----------------------|--|--|--|--|
| _ | | Institution | Institution No | |
| lf t | his is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No | |
| | structions: The CD form is completed by the Site Radiologist to nth visit. This form is submitted via the ACRIN website. | document findings on the Ch | est CT scan performed at the 18 | |
| 1. | Was a chest CT scan performed at 18 months? [1] | 8. Indicate the results | of this scan | |
| | O No (Answer Q2) | O Negative (Complet | e Q8a) _[10] | |
| | O Yes (Skip to Q3) | | indicate clinical significance [11] | |
| 2. | If no, give reason (then sign and date form) O Scheduling problems O Equipment failure O Participant refusal O Medical reasons O Injection site complications O Claustrophobia O Participant withdrew consent O Progressive disease O Participant death O Other, specify O Unknown Date of Chest CT scan | O No signif O Minor ab for pulm O Significa pulmona O Positive (Complete 8b. If positive, for pulmon O Low sus O Intermed O Moderate O High sus | ficant abnormalities conormalities not suspicious conary metastases nt abnormalities not suspicious for cry metastases a Q8b) [12] indicate overall suspicion cary metastases [13] spicion diate suspicion ely high suspicion | |
| Э. | (mm-dd-yyyy) | 8c. If inadequa | ite/suboptimal, indicate reason [15] | |
| 4. | Date of Chest CT interpretation (Date CT scan reviewed by Study Radiologist) | O Noisy im O Patient n O Metal ar | notion | |
| 5. | Reader ID [6] | | | |
| 6. | Was a Helical Chest CT scan performed with slice thickness of 5 – 8 mm? [7] O No (If no, please submit a PR describing the deviation) O Yes O Other, specify [8] | | | |
| 7. | Chest CT scan performed [9] | | | |

"Copyright 2008"

O With intravenous contrast O Without intravenous contrast

ACRIN 6673

ACRIN Study 6673

| Chest CT Imaging Form If this is a revised or corrected form, please √box. | PLACE LABEL HERE | |
|---|-------------------|----------------------------------|
| | | Institution No |
| | | Case No |
| | | |
| | | |
| | | |
| Comments: | | |
| | | |
| | | |
| | | |
| | | [17] |
| | | |
| | [—] [18] | |
| Signature of Site Radiologist | | Date Form Completed (mm-dd-yyyy) |
| | | |
| | | |
| | | |
| | | |

C8 Ce

ACRIN 6673 Central Reader Chest CT Interpretation Form

| ACRIN | Study | 6673 |
|--------------|-------|------|
|--------------|-------|------|

PLACE LABEL HERE

| | Institution Institution No |
|---|---|
| If this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials Case No |
| Instructions: The central reader is to complete one C8 form for each YYYY. All responses are required unless otherwise noted. This form | |
| 1. Protocol timepoint [1] O 1 Baseline O 2 18 month O 88 Other, specify[2] 1a. Date of scan | 4. Is tumor present? [15] O 1 No (Initial and date form) O 2 Yes (complete Q4a) O 3 Indeterminate (complete Q4a) 4a. Location of tumor (excluding extra-thoracic) [mark all that apply: □ = 1 Not Marked, □ = 2 Marked] □ Pulmonary [16] |
| 2. Reader ID | ☐ Mediastinum [17] |
| Image Quality: | ☐ Bone [18] |
| 3. Interpretable? O 1 No (complete 3a, then initial and date form) O 2 Yes (skip to Q4) 3a. Reason [mark all that apply: □ = 1 Not Marked, ☑ = 2 Marked] □ Motion [6] □ Artifacts [7] □ Contrast media [8] □ DICOM header [9] □ Lost images [10] □ Poor S/N [11] □ Incomplete anatomic coverage [12] □ Other [13] specify[14] | |
| Comments: | [21] |
| Reader Initials | Date form completed (mm-dd-yyyy) |
| Initials of person completing form | |

| 00 | ACRIN 6673 | |
|----|-------------------------------|------|
| 62 | ACRIN 6673 Initial Imaging | Form |

| ACRIN | Study | 667 | 3 |
|---------|-------------|------|------|
| PLACE I | LABE | EL E | HERE |

| └ ∠ Initial Imaging Form | PLACE LABEL HERE | | |
|--|---|--|--|
| | Institution Institution No | | |
| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | Participant Initials Case No | | |
| Initial Imaging Form After enrollment, the Initial Imaging form (C2) is to be completed by A C2 form is completed for each tumor and is based on an abdom the diagrams (page 2, question 8) with a "t" within the appropriate swebsite www.acrin.org a copy of page 2 of the C2 form must be made affixed to the form in the designated area. | ninal scan using either CT or MRI. The tumor is marked within segment. Once the form data has been entered into the ACRIN | | |
| 1. Reader ID#: 2. Type of abdominal scan O CT O MRI 2a. Date of abdominal scan: ——————————————————————————————————— | 6. Imaging findings of cirrhosis present? O No (skip to Q7) O Yes (complete Q6a) 6a. Check all that apply: Nodular Liver Hepatic atrophy/hypertrophy Portal varices Splenomegaly Ascites 7. Number of per protocol tumors for ablation present: O 1 O 2 O 3 8. Are there hypervascular lesions (non-protocol lesions) present < 1 cm? O No O Yes | | |
| O Yes |) is mailed to the Data Management center. | | |

American College of Radiology ACRIN 6673/Data Management 1818 Market Street/Suite 1600 Philadelphia, PA 19103

| ACRIN STUDY 6673 Initial Imaging Form | Case # | AC | RIN Study 6673 E LABEL HE | RE n No |
|---|--------------|----------------------|------------------------------|-------------------|
| Complete description of each | tumor | Participant Initials | | |
| 9. This form represents: Tumor Number (Numbering and location must be consistent throughout the study.) | | | | |
| Diagram of the Liver (Appendix VI) *Couinaud Segments: | | | | |
| VIII |) / / / viii | | Segment | 1 |
| VII | | 7 | Segment | II |
| | | | Segment | III |

9a. Mark location of this tumor on the diagram with a "t".

| 9b. | Date of Abdominal Scan | Couinaud Liver Segment* (Check all that apply for this tumor) Segment I Segment II | Size (cm) Largest Size in Diameter | Subcapsular | Contiguous to Major Vessels? (vessels > 5mm) | Does the tumor meet the criteria for RFA treatment as outlined in the protocol? |
|-----|------------------------------|---|--|---------------|--|--|
| | 20 | □ Segment III □ Segment IVA | | o No o Yes | o No o Yes | o No o Yes |
| | (mm/dd/yyyy) | □ Segment IVB □ Segment V □ Segment VI □ Segment VIII □ Segment VIII | | 0 700 | 0 763 | 0 703 |

| Comments: | | |
|---|----------------------------------|---------------------------|
| Signature of person responsible for the data ¹ | Date form completed ³ | 20 (mm-dd-yyyy) |
| Signature of person entering data onto the web ² | | |

Segment

Segment

Segment

Segment

Segment

Segment

IVA


IVB

٧

VI

VII

VIII



ACRIN Study 6673 **PLACE LABEL HERE**

| Tumor Resectability | Institution | Institution No |
|---|-------------------------|--|
| If this is a revised or corrected form, indicate by checking box. | Patient's Initials | Patient's I.D. No. |
| Instructions: This form must be completed by the Surgical C | Oncologist. | |
| 1. Is the participant a candidate for liver resection?O No (complete 1a)O Yes | | |
| 1a. Reason: (Select all that apply) | | |
| Tumors in unresectable location. | | |
| Co-morbid disease making the patient a po | oor surgical candidate. | |
| Insufficient hepatic reserve. | | |
| | | |
| | | |
| | | |
| Comments: | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| Signature of Surgical Oncologist ¹ | Date form comple | eted ³ 20 (mm-dd-yyyy) |
| | | , , , , , , , , , , , , , , , , , , , |
| Signature of person entering data onto the web ² | | |
| | | |
| | | |

ACRIN Study 6673

| [Abdominal Scari] | PLACE LABEL HERE | | |
|---|--|---|--|
| | Institution | Institution No | |
| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | Participant Initials | Case No | |
| Instructions: The adjudicator is to review the abdominal scans for each cast imors and tumor descriptors. All dates are reported as MM/DD/YYYY. All indicate entered at ACRIN headquarters. The ACRIN Case Number and Follow-Up Time Period must be recommended. | responses are required unless otherw | vise noted. This form will be completed | |
| Section I. | Section II. | | |
| Pre-enrollment O 2 Baseline (initial post-ablation) O 3 3 Month O 4 6 Month O 5 9 Month O 6 12 Month O 7 15 Month O 8 18 Month O 88 Other, specify | O 1 No (skip Q4a O 2 Yes (comple: | te Q4a and Section III) : □ = 1 Not Marked, □ = 2 Marked] | |
| Date of Scan: (mm-dd-yyyy) [3] Reader ID [4] | Lymph node Lymph node Musculoskele Pancreas | etal _[20] 1 | |
| nage Quality: | ☐ Spleen _[23] | • | |
| Interpretable? [5] O 1 No (complete 3a, then initial and date form) O 2 Yes (skip to Q4) 3a. Reason [mark all that apply: □ = 1 Not Marked, □ = 2 Marked] | ☐ Abdominal w | rall _[24] ecify [26] | |
| Motion | | | |

1 of 5

ACRIN Study 6673

PLACE LABEL HERE

| , | Institution | Institution No. |
|--|----------------------|-----------------|
| If this is a revised or corrected form, please √box. | Participant Initials | Case No |

Section III.

TUMOR REPORT

- * Tumor numbering and location(s) must be consistent throughout the adjudicator reader interpretation per follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|---|--|---|---------------------------------------|
| [27] | | [29] O 1 Ablated O 2 Not ablated | Segment I [30] Segment V [35] Segment II [31] Segment VI [36] Segment III [32] Segment VII [37] Segment IVA [33] Segment VIII [38] Segment IVB [34] | [39] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [40] O 1 No O 2 Yes | [41] |
| [42] | [43] | O 1 Ablated O 2 Not ablated | Segment I [45] Segment V [50] Segment II [46] Segment VI [51] Segment III [47] Segment VII [52] Segment IVA [48] Segment VIII [53] Segment IVB [49] | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [55] O 1 No O 2 Yes | [56] |
| [57] | [58] | [59] O 1 Ablated O 2 Not ablated | Segment I [60] Segment V [65] Segment II [61] Segment VI [66] Segment III [62] Segment VII [67] Segment IVA [63] Segment VIII [68] Segment IVB [64] | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [70] O 1 No O 2 Yes | [71] |
| [72] | [73] · | [74] O 1 Ablated O 2 Not ablated | Segment I [75] Segment V [80] Segment II [76] Segment VI [81] Segment III [77] Segment VII [82] Segment IVA [78] Segment VIII [83] Segment IVB [79] | O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [85] O 1 No O 2 Yes | [86] |
| [87] | [88] · | [89] O 1 Ablated O 2 Not ablated | Segment I [90] Segment V [95] Segment II [91] Segment VI [96] Segment III [92] Segment VII [97] Segment IVA [93] Segment VIII [98] Segment IVB [94] | [99] O 1 Tumor absent O 2 Tumor present O 3 Indeterminate | [100] O 1 No O 2 Yes | [101] |

"Copyright 2009" Version 2.0 6673 AS 08-25-09 2 of 5

ACRIN Study 6673

PLACE LABEL HERE

| | Institution | Institution No. ———— |
|---|----------------------|----------------------|
| this is a revised or corrected form, please $\sqrt{\text{box}}$. | Participant Initials | Case No |
| ` | \ | |

TUMOR REPORT

- * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|--|---------------------------------------|--|---------------------------------------|
| [102] | [103] | [104] O 1 Ablated O 2 Not ablated | Segment I [105] Segment V [110] Segment II [106] Segment VI [111] Segment III [107] Segment VII [112] Segment IVA [108] Segment VIII [113] Segment IVB [109] | O 1 Tumor absent O 2 Tumor present | [115] O 1 No O 2 Yes | [116] |
| [117] | [118] | [119] O 1 Ablated O 2 Not ablated | Segment I [120] Segment V [125] Segment II [121] Segment VI [126] Segment III [122] Segment VII [127] Segment IVA [123] Segment VIII [128] Segment IVB [124] | O 1 Tumor chaont | [130] O 1 No O 2 Yes | [131] |
| [132] | [133] | [134] O 1 Ablated O 2 Not ablated | Segment I [135] Segment V [140] Segment II [136] Segment VI [141] Segment III [137] Segment VII [142] Segment IVA [138] Segment VIII [143] Segment IVB [139] | O 1 Tumor absent | [145] O 1 No O 2 Yes | [146] |
| [147] | [148] | [149] O 1 Ablated O 2 Not ablated | Segment I [150] Segment V [155] Segment II [151] Segment VI [156] Segment III [152] Segment VII [157] Segment IVA [153] Segment VIII [158] Segment IVB [154] | O 1 Tumor absent | [160] O 1 No O 2 Yes | [161] |
| [162] | [163] | [164] O 1 Ablated O 2 Not ablated | Segment I [165] Segment V [170] Segment II [166] Segment VI [171] Segment III [167] Segment VII [172] Segment IVA [168] Segment VIII [173] Segment IVB [169] | O 1 Tumor absent | [175] O 1 No O 2 Yes | [176] |

"Copyright 2009" Version 2.0 6673 AS 08-25-09 3 of 5

ACRIN Study 6673 PLACE LABEL HERE

| . — | Institution | Institution No. ————— |
|--|----------------------|-----------------------|
| this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials | Case No. |
| | | |

TUMOR REPORT

- * Tumor numbering and location(s) must be the same on every central reader form across all follow-up time periods.
- ** Local read tumor match number is to be completed after the last follow-up form is completed. Enter "88" if no local tumor matches the tumor found by the central reader.

| *Tumor Number | Tumor Size (cm) | Ablation Status Per Follow-Up Time Period | *Tumor Location Couinaud Liver Segment [mark all that apply: = 1 Not Marked, = 2 Marked] | Tumor Status | Are there additional tumors to report? | **Local read Tumor match Number |
|------------------|-----------------------|---|--|---------------------------------------|---|---------------------------------------|
| [177] | [178] | [179] O 1 Ablated O 2 Not ablated | Segment I [180] Segment V [185] Segment II [181] Segment VI [186] Segment III [182] Segment VII [187] Segment IVA [183] Segment VII [188] Segment IVB [184] | O 1 Tumor absent O 2 Tumor present | [190] O 1 No O 2 Yes | [191] |
| [192] | [193] | O 1 Ablated O 2 Not ablated | Segment I [195] Segment V [200] Segment II [196] Segment VI [201] Segment III [197] Segment VII [202] Segment IVA [198] Segment VII [203] Segment IVB [199] | O 1 Tumor absent | [205] O 1 No O 2 Yes | [206] |
| [207] | [208] | O 1 Ablated O 2 Not ablated | Segment I [210] Segment V [215] Segment II [211] Segment VI [216] Segment III [212] Segment VII [217] Segment IVA [213] Segment VIII [218] Segment IVB [214] | O 1 Tumor absent O 2 Tumor present | [220] O 1 No O 2 Yes | [221] |
| [222] | [223] | O 1 Ablated O 2 Not ablated | Segment I [225] Segment V [230] Segment II [226] Segment VI [231] Segment III [227] Segment VII [232] Segment IVA [228] Segment VIII [233] Segment IVB [229] | O 1 Tumor absent | [235] O 1 No O 2 Yes | [236] |
| [237] | [238] | [239] O 1 Ablated O 2 Not ablated | Segment I [240] Segment V [245] Segment II [241] Segment VI [246] Segment III [242] Segment VII [247] Segment IVA [243] Segment VIII [248] Segment IVB [244] | O 1 Tumor absent | [250] O 1 No O 2 Yes | [251] |

"Copyright 2009" Version 2.0 6673 AS 08-25-09 4 of 5

ACRIN Study 6673 PLACE LABEL HERE

| If this is a revised or corrected form, please $\sqrt{\text{box}}$. | | Institution No |
|--|--------------------|----------------------------------|
| | | |
| | | |
| Section IV. | | |
| Comments: | | |
| | | |
| | | [252] |
| Reader Initials | ⁻ [253] | Date form completed (mm-dd-yyyy) |
| Initials of person completing form | ⁻ [255] | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |

"Copyright 2009"

5 of 5



ACRIN Study 6673 PLACE LABEL HERE

| | Institution Institution No |
|---|--|
| If this is a revised or corrected form, please $\sqrt{\text{box.}}$ | Participant Initials Case No |
| Instructions: This data is assessed by the adjudicator at ACRIN He form. All dates are reported as MM/DD/YYYY. All responses are requ | · |
| 1. Protocol timepoint [1] | 4. Is tumor present? [15] ○ 1 No (Initial and date form) ○ 2 Yes (complete Q4a) ○ 3 Indeterminate (complete Q4a) 4a. Location of tumor (excluding extra-thoracic) [mark all that apply: □ = 1 Not Marked, □ = 2 Marked] □ Pulmonary [16] □ Mediastinum [17] □ Bone [18] □ Other [19] specify [20] |
| Comments: | [21] |
| Reader Initials | Date form completed (mm-dd-yyyy) |
| Initials of person completing form | |

APPENDIX II

| REGISTRATION/E | LIC | GIBILITY CHECK (Page 1 of 3) |
|--|----------|---|
| ACRIN 6673 | | |
| ACRIN Institution # | <u> </u> | ACRIN Case # |
| Eligibility Requiren participant ineligible | | ts: Inclusion Criteria - a response coded other than what is prompted renders a enrollment. |
| (Y) | 1. | Biopsy proven cirrhosis, or typical findings of cirrhosis by CT scan. |
| (Y) | 2. | Hepatocellular carcinoma (HCC) proven by: (Check all that apply) |
| | | (|
| | | Biopsy |
| | | ☐ Barcelona imaging criteria [see Appendix VIII, #3] |
| | | ☐ Barcelona combined criteria [see Appendix VIII, #3] |
| | | ☐ Tumor growth criteria [see Appendix VIII, #4] |
| | 3. | Hepatic tumor burden meeting the Milan Criteria. |
| | | O 3 or fewer tumors \leq 3.0 cm or |
| | | O a single tumor > 3.0 cm but ≤ 5 cm in diameter |
| (Y) | 4. | All identified tumors are treatable by percutaneous RFA: all tumors are ≥ 1 cm from the main, right and left portal veins and all tumors are ≥ 1 cm from hollow viscera. |
| (0-2) | 5. | Record performance scale as defined by the Zubrod Performance Scale. [see Appendix V and 5.3.6] |
| (Y) | 6. | Serum creatinine $\leq 2.0 \text{ mg/dl}$. |
| (Y) | 7. | Chest and abdominal CT scan within 60 days of initial RFA treatment. |
| (Y) | 8. | Aspirin and nonsteroidal anti-inflammatory medications, anti-platelet medications or wafarin has been discontinued for a time period that is appropriate given the drug half-life or its known anti-platelet activity (e.g., aspirin for 7 days and ibuprofen 24 hours) prior to the scheduled RFA. |
| (Y) | 9. | All laboratory requirements as described in section 5.3.3 of the protocol have been met. |
| Eligibility Requirement participant ineligible | | ts: Exclusion Criteria - a response coded other than that prompted renders a enrollment. |
| (N) | 10 | . Participant has had prior treatment for HCC by any method. [see Section 5.1.12] |
| (N) | 11 | . Surgical candidate. [see Appendix IX] |
| (N) | 12 | . Hepatic or portal vein tumor invasion. |
| (N) | 13 | . Extrahepatic tumor. |
| | | |

| ACRIN 6673 | | ACRIN Case # |
|-------------------|---------|--|
| | _(N) | 14. Active infection. [see Section 5.2.12] |
| | _(N) | 15. History of cholendochoenteric anastomosis and or spincterotomy of duodenal papilla. |
| | _(N) | 16. Absolute contraindication to intravenous iodinated contrast. [see Section 5.2.15] |
| The following | questio | ons will be asked at Study Registration: |
| | 1. | Name of institutional person registering this case. |
| | (Y)2. | Has the Eligibility Checklist (Inclusion/Exclusion Q1-16) been completed? |
| | _(Y)3. | Is the participant eligible for this study? |
| / / | 4. | Date the study-specific Consent Form was signed (mm/dd/yyyy) (must be prior to study entry) |
| | 5. | Participant Initials (last, first): Numeric number may be coded other than the assigned case number, ####. |
| | 6. | Verifying Physician (Site PI) |
| | 7. | Participant's ID Number (optional: this is an institution's method of tracking participant to a case number; code 99999) |
| / | 8. | Date of Birth (mm-dd-yyyy) |
| | 9. | Ethnic category 1 Hispanic or Latino 2 Not Hispanic or Latino 9 Unknown |
| | 10. | Race (Check all that apply. ☐ 1 = No, ☐ 2 = Yes) American Indian or Alaskan Native Asian Black or African American Native Hawaiian or other Pacific Islander White Unknown |
| | 11. | Gender 1. Male 2. Female (Complete question 20, negative pregnancy test) |

| <u>REGISTRATION/EL</u> ACRIN 6673 | ACRIN Case # |
|--------------------------------------|--|
| 12. | Participant's country of residence (if country of residence is other, proceed Question 13 for completion) 1 United States (Complete question 14, Zip code) 2 Canada 3 Other (Complete question 13, Other country, specify) 9 Unknown |
| 13. | Other Country, specify (completed if Q12 is coded 'Other') |
| 14. | Zip code (5 digit code, completed if Q12 is coded 'United States') |
| 15. | Participant's Insurance Status 0 Other 1 Private Insurance 2 Medicare 3 Medicare and Private Insurance 4 Medicaid 5 Medicaid and Medicare 6 Military or Veterans Administration 7 Self pay 8 No means of payment 9 Unknown/Decline to answer |
| 16. | Will any component of the participant's care be given at a military or VA facility? 1 No 2 Yes 9 Unknown |
| <u>//</u> | Initial RFA Treatment Date (mm/dd/yyyy) |
| / 18. | Registration Date (mm/dd/yyyy) |
| 19. | MELD Score: |
| | O Score > 25 |
| | O Score 15 – 25 |
| | O Score < 15 |
| (¥) 20. | If female, negative pregnancy test within 24-hours of RFA treatment? |
| (Y/N) 2 | 21.Does the participant have a pacemaker? |
| Study Participant Signa | nture: Date:/ |
| , | |

Signature of person entering data onto the Web _____